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PREFACE 
This r~port documents the activities of the Research Triangle Institute1s Biomedical Applications Team 
program for the period 1 January 1982 through 28 February 1983. The work was performed in the Research 
Triangle Institute1s Center for Technology Applications under the direction of Dr. D. J. Rouse. Dr. J. N. 
Brown, Jr., Director of the Center, participated in the methodology development and management of the 
team. Assistance in establishing collaborative projects with the National Institutes of Health and other 
Federal agencies was provided by Mr. William Z. Penland, Jr., and Mr. Bernard Maggin, RTI consultants 
in Washington, D. C. Other participants in the program were Dr. H. C. Beall, Mr. P. N. Kizakevich, and 
Ms. B. Bass. The team was as~isted during the summer by Mr. Scott Fosko. To ensure close coordination 
of transfer projects in California, RTI supported SRI InternationaPs participation in the projects as an RTI 
team representative . 
The work reported herein was supported by the National Aeronautic~ and Space Administration--
Contract No. NAS1-16177. Mr. John Samos, Head, Technology Utilization and Applications Programs Office, 
Langley Research Center, was the technical monitor. . 
The authors gratefully acknowledge the contributions of many individuals to the success of the RTI 
Biomedical Applications Team program. The time and effort contributed by Technology Utilization officers, 
managers, engineers, and scientists throughout the National Aeronautics and Space Administration and by 
medical researchers and clinicians were absolutely essential to program success. Industry managers and 
technical staff have always been cooperative and open in their participation. Continuing discussions with 
these industry representatives have enhanced the team1s understanding of medical device manufacturing and 
marketing practices and constraints. Finally, Mr. John Samos has contributed significantly to the success 
of the program and, as a technical monitor, has always been supportive. 
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ABSTRACT 
The objective of the Research Triangle Institute (RTI) Biomedical Applications Team is to achieve wide-
spread utilization of ~ational Aeronautics and Space Administration (NASA) technology in medicine. This 
objective is best obtained by stimulating the. introduction of new or improved commercially available medical 
products incorporating aerospace technology. 
A bipolar donor-recipient model of medical technology transfer is presented to provide a basis for the 
team's metl1odology. That methodology is designed to: (1) identify medical problems and NASA technology 
that, in combination, constitute opportunities for successful medical products; (2) obtain the early partic-
ipation of industry in the transfer process; and (3) obtain acceptance by th~ medical community of new 
medical products based on N~SA technology. 
During the reporting period, th~ team completed two commercial transfers: the Ocular Screening 
Device, a· system for quick detection of vision problems in preschool children, and Porta-Fib III, a hospital 
monitoring unit. The team also completed two institutional transfers: implant materials testing, the appli-
cation .of NASA fracture control technology to improve reliability of metallic prostheses, and incinerator 
monitoring, a quadrupole mass spectrometer to monitor combustion products of municipal incinerators. 
Two Phase 0 studies wer~ completed by the team during the reporting period: Mobility Aids for the 
Blind (;!nd Ultrasound Diagnosis of Burn Depth. 
The team identified six new projects. Five projects were inactivated due to inadequate commercial 
potential to justify continued development. During the operating period, progress was made in the devel-
opment and commercialization of each of the fifteen currently active projects. 
For the convenience of the reader, the names and addresses of the sources of certain commercial 
products are included in this report. This listing does not !=onstitute an endorsement by eith~r the 
National Aeronautics and Space Administration or the Research Triangle Institute. 
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.1.0 INTRODUCTIOf':J 
The preamble to the Space Act of 1958, which created the National Aeronautics and Space Administration 
(NASA), states: lilt is the policy of the United States that activities in space should be devoted to 
peaceful purposes for the benefit of all mankind ."1 This Act of Congress further charges NASA with 
providing "for the widest practical and appropriate dissemination of information concerning its activity and 
the results thereof. II The NASA Technology Utilization Program was initiated in 1962 to assist in satisfying 
this Congressional obligation. 
Since 1962, NASA has been a leader and an innovator in the establishment, operation, and evaluation of 
technology transfer programs. Through its Tech Briefs, special publications, technology surveys, and 
Industrial Applications Center programs, NASA has successfully transferred the results of aerospace 
research to the non-space-related sectors of society. 2 
The NASA Appropriations Act for fiscal year 1979 amended the 1958 Space Act to emphasize the application 
of aerospace technology to bioengineering research. 3 The following subsection was added to Section 102 of 
the Space Act: 
The Congress declares that the general welfare of the United States requires that the unique 
competence of the National Aeronautics and Space Administration in science and engineering 
systems be directed to assisting in bioengineering research, development and demonstration 
programs designed to alleviate and minimize the effects of disability. 
In 1966, NASA introduced a new approach to technology transfer that involved the activities of multidisci-
plinary "applications teams. II The objective of these applications teams--called Biomedical Applications 
Teams--was to effect the transfer of NASA technology to applications in medical research and clinical med-
ICine. The general approach of the Biomedical Applications Teams was: (1) to identify problems through 
direct interactions with clinicians and medical researchers, (2) to identify potentially applicable NASA tech-
nology by a variety of mechanisms, and (3) to take necessary and appropriate action to effect actual utili-
zation of NASA technology in solving technology-related medical problems. 
The Research Triangle Institute (RTI) has participated in this program since 1966, when it established one 
of the first three NASA Biomedical Applications Teams. Since then, the Institute has made a major commit-
ment to the successful transfer of aerospace technology to applications in medicine and to a better under-
standing and advancement of the technology transfer process. 
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1.1 Biomedical Applications Team Objectives 
The primary. objective of the Biomedical Applications Team program is to assist NASA in achieving 
widespread utilization of aerospace technology in the medical field. Widespread utilization implies that 
application of NASA technology to medicine benefits a significant sector of the medical field and of 
those seeking medical services. Implicit in this program objective is the rapid realization of this wide-
spread utilization. 
The successful transfer of. NASA technology to applications in the medical field via the Biomedical Ap-
plications Team program has been demonstrated 2 4 both in clinical medicine and in medical research. 
These applications have resulted in. advances in medical research, improved clinical diagnoses and 
treatments, and the introduction of new or improved medical products. 
Although ad.v.ances. in medical research ultimately have widespread positive impact on the delivery of 
health care in the United States, medical research is a slow, complex, and expensive process. How-
ever, much can be accomplished in. a relatively short time by solving technology-related problems in 
clinical medicine. Applications of technology in clinical medicine usually involve the introduction of a 
new or improved commercially available medical product. Thus, the approach of the NASA Biomedical 
Applications Teams in obtaining, widespread utilization of NASA technology is to concentrate on solving 
problems, that involve the introduction of a new or improved medical product. 
This. emphasis on achieving, widespread utilization by commercializing NASA technology is reflected in 
the activities. and methodology. of the Biomedical Applications Team program. The team methodology 
has been built around the· following four activities: (1) identifying medical problems and needs and 
potentially applicable NASA technolog,ies that together constitute a new or improved medical product; 
(a) screening, opportunities. to, find those that represent potentially successful commercial products; 
(3) developing commercialization strategies that take into account any necessary adaptation of NASA 
technoloQ;'t" evaluations and. clinical trials, FDA regulations, manufacturer's marketing systems, and 
required funding; and, (4). implementing and monitoring commercialization strategies. These tasks are 
discussed: in more detail in Section 2'.0", Technical Approach. 
1.2 Biomedical Applications Team Staffing 
The RTI. Biomedical Applications Team is a multidisciplinary team of engineers and scientists whose 
educational backgrounds include physiology, biophysics, engineering, biochemistry, and biomedical 
engineering and; whose experience includes basic and applied research, product development, and 
marketing .. The team is necessarily multidisciplinary in nature because the transfer of technology to 
the medical field is an interdisciplinary process. That is, team members must communicate precisely 
and ~ffectively with physicians, NASA scientists and engineers, industry representatives, and repre-
sentatives of a variety of government agencies. Furthermore, the team must be able to deal with and 
contribute to the technical, clinical, financial, legal, marketing, and regulatory aspects of introducing 
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new medical products. The individuals who participated in the RTI Biomedical Applications Team pro-
gram during the reporting period are: 
Name Professional Background 
Dr.J. N. Brown, Jr. Electrical Engineer 
Dr. D. J. Rouse Biochemist, Physiologist 
Dr. H. C. Beall Biophysicist, Physiologist 
Mr. William Z. Penland, Jr. Engine~r 
Mr. Scott Fos ko Microbiology 
. Mr. P. N. Kizakevich f3iomedical Engineer 
Mr. Bernard Maggin Program Manager 
Dr. Anthony Marmarou Electrical Engineer 
Ms. B.C. Bass Resource Specialist 
1.3 Participating Institutions 
Responsibility 
Director, Center 
. for Technology 
Applications 
Director, RTI Biomedical 
Applications Team 
Solution Specialist 
Washington Consultant 
Summer I nt~rn 
I nternal Technical 
Consultant 
Washington Consultant 
Neurosurgery Consultant 
Solution Assistant 
Biomedical Applications Teams may be viewed as one component in a technology transfer network that 
involves NASA Headquarters, NASA field centers, medical institutions, manufacturing and marketing 
firms, the National Institutes of Health (NIH), the Food and Drug Administration (FDA), and other 
government agencies. Organizations and their roles in the technical process are listed below. 
Organization 
National I nstitutes of Health 
Veterans Administration 
National Aeronautics and Space 
Administration 
3 
Role' 
Establishment of medical objectives and 
prioritie~ and evaluation of devices 
Development of advanc~d technology and 
innovations 
Organizatic>n 
,Me.clic.al institutions 
Industry 
Biomeclical Applications T~iilms 
FOOQ .anO Drug Administration 
Role 
Specification of needs and use of medical 
innovations 
Manufacture and distribution of products 
C.oordination, planning, and reporting 
Approval of products and establishment of 
medical objectives and priorities 
At pr.es~nt, medic.aI researchers and clinicians from 26 medical institutions participate in the RTI Bio-
medic.al Applications Teqm progri;lm. Mec:!ical research~rs and clinicians participate in the program by: 
(1 )id~ntifying medJ,cpl prqblems and needs appropriat~ for investigation by the Biomedical Applications 
Team; (2) serving as a I$nowJedg~ ppse on me.dicc;lI problems and needs, markets, and potential appli-
cations of NASA technologYi .:incl (3) r.eceiving NASA technology to be applied in their medical research 
programs pr :to .be eVpl,uated within their clinical practices. Figure 1 presents the geographical loca-
tions ,of p.articipating meoiYlI instituUons and NASA field centers. Table 1 lists these medical institu-
tionsJ anp T.:ibJ.e2 lists the RTJ 13 i.ornedica I Applications Team active projects at the NASA field centers 
for the ppst year. 
The active' Participation of mecl.ical device m.anufacturers is essential to the widespread utilization of 
NA$A technology beql.lJse they incorporate that technology into commercial medical products. Manu-
facturers who hav~ par:ticippte.d .in the RTI Biomedical Applications Team program during thisr.eporting 
periqd are .Iist~d in Table 3. 
Government agencies ,involy.edin health care research, regulation, and clelivery work with the RTI team 
tq identify significant projects and to fpcilitate their successful completion. Agencies participating in 
RTJls team projects during this reporting period pre listed in Table 4. 
1..4 Conference Attendance and Advisory Boards 
Tqinfgrrri' the medical .community of NASNs technology transfer program in medicine, RTI team mem-
ber,S piilrticipate in biqmedical conferences .and serve on national advisory boards. In lVIarch 1982, 
.or. ().oris Rouse made a pr.esentation on the NASA technology transfer program at the Wheelchair III 
conf.eren.ce sponsqred by th~ Vetercms Admini.stration. Th.e RTI team also participated in the annual 
conference qf the .Rehabilitation .Engineering Society of North America (RESNA) in August. Dr. Doris 
Ro.usew,as as,ked to chair the R.ESNA wheelchair committee. I n November, the RTI team attended an 
International Wqrkshop on Hydrocephalus. In the past year the RTI team was asked to serve on the 
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Figure 1. Biomedical Technology Transfer Network. 
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T~BLE 1.PARTICIPAT.ING MEDICAL INSTITUTIONS 
Alabama 'School for the Deaf 
Albert Einstein ,College of Medicine . 
Case Western Reserve University 
Cornell Medical Center 
Duke University Medical Center (including VA Hospital) 
Johns Hopkins University Medica! School 
M.D. Anderson Hospital 
Medical College of Virginia 
Montefiore Hospital 
Rochester General Hospital 
Rush-Presbyterian Medical Center 
st. Mary·s Hospital 
Shriners Burn Institute 
Smith-Kettlewell Eye Research Foundation 
Texas Institute for Rehabil itationand Research 
U.S. Army Institute of Surgical Research 
University of Alabama Department of Rehabilitation 
University of Arizona Medical School 
University of California-I rvine 
University of Mississippi Medical Center 
University of North Carolina School of Medicine 
University of Virginia Rehabilitation Engineering Center 
University of Virginia School of Medicine 
Veterans Administration Hospital 
Veterans Administration Rehabilitation Engineering Center 
Wadley. Institute 
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Talladega, AL 
Bronx, NY 
Cleveland ,OH 
New York, NY 
Durham, NC 
Baltimore, MD 
Houston, TX 
Richmond, VA 
New York, NY 
Rochester, NY 
Chicago, IL 
Richmond, VA 
Boston, MA 
San Francisco, CA 
Houston, TX 
San Antonio, TX 
Birmingham, AL 
Tucson, AZ 
Irvine,CA 
Jackson, MS 
Chapel Hill, NC 
Charlottesville, VA 
Charlottesville, VA 
Norfolk, VA 
Palo Alto, CA 
Dallas, TX 
) 
TABLE 2. PROJECTS WITH NASA FI ELD CENTERS DURING REPORTING YEAR 
AMES RESEARCH CENTER 
Digital Data R~corder for Physiological Monitoring 
Liquid-Cooled Garment Projects 
Cooling Vests for Quadriplegics 
Cooling for Multiple Sclerosis Therapy 
Mobility Aids for the Blind 
GODDARD SPACE FLIGHT CENTER 
Computerized Hydrocephalus Implantable Pump 
Programmable Implantable Medication System 
JET PROPULSION LABORATORY 
Corneal Topography 
Hydrocephalus Shunt--Ventilation 
JOHNSON SPACE CENTER 
Female Incontinence Device 
Flow Sensor for an I nfusion Pump 
Physician's Black Bag 
KENNEDY SPACE CENTER 
High Performance Wheelchair 
Wildlife Tracking 
LANGLEY RESEARCH CENTER 
Aircraft Whe~lchair 
Composite Material Applications 
Fiber Optics for Knee Surgery 
High Performance Wheelchair 
Implant Materials Testing 
I ncinerator Monitoring 
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LANGLEY RESEARCH CENT~R (continued) 
Low-Cqst UV Optical Dosimeter 
Microwave Thermography 
Noninvasive Lung Dia.gnosis 
Portable X-Ray Fluorescense Spectrometer 
Ultras9und Diagnosis of Burn Depth 
Weight Alleviation Device 
LEWIS RESEARCH CENTER 
Detection of a Dislodged Temperature Probe 
Hydrocephalus Shunt--Ventilation 
Texturing for Percutaneous Connectors 
Texturing Surfaces for Cardiovascular 
Prostheses 
MARSHALL SPACE FLIGHT CENTER 
Corneal Topography 
Detection of a Dislodged Tempera-
ture Probe 
Ocular Screening Device 
Prosthetic Urinary Sphincter 
NATIONAL SPACE TECHNOLOGY 
LABORATORIES 
Wastewater Treatment by Vascular 
Aquatic Plants 
TABLE 3. MANUFACTURERS PARTICIPATING IN BATEAM PROJECTS 
Abbott Laboratories 
Air Transport Association 
American Hospital Supply 
Analog Technology Corporation 
Applied Medical Technology, Inc. 
B&K Instruments 
Boeing Aircraft 
Becton·Dickinson 
CAM I Health Care, Inc. 
Cordis Corporation 
Design Research Associates, Inc. 
Eagle EngineOering Corporation 
Electro·Optics Consultants, Inc. 
Everest & Jennings 
Hercules, Inc. 
Heyer Schulte Corporation 
I nvacare Corporation 
Inductron 
Johnson & Johnson 
Major Laboratory 
Medical Engineering Corporation 
Microwave Associates, Inc. 
Miller Medical Electronics 
NARCO Bio-Systems, Inc. 
Pacesetter Systems, Jnc. 
Palm Beach Medical Corporation 
Parker·Hannifin Corporation 
Patscenter International, Inc. 
Preston Company 
Pudenz-Schulte Medical Research Corporation 
Scientific Industries 
Sonometric Systems, Inc. 
Thermo Electron Corporation 
Uniteq Airlines 
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Houston, TX 
Washington, DC 
Glendale, CA 
Sunnyvale, CA 
Lakewood, OH 
Cleveland, OH 
Seattle, WA 
Rutherford, NJ 
League City, TX 
Miami, FL 
Tulsa, OK 
Houston, TX 
Huntsville, AL 
Los Angeles, CA 
Washington, DC 
Goletka~ CA 
Elyria, OH 
Grafton, VA 
New Brunswick, NJ 
Oklahoma City, OK 
Racine, WI 
Burlington, MA 
San Diego, CA 
Houston, TX 
Sylmar, CA 
E. Long Meadow, MA 
Irvine, CA 
Princeton, NJ 
New York, NY 
Irvine, CA 
Bohemia, NY 
New York, NY 
Waltham, MA 
San Francisco, CA 
TABLE 4. AGENCIES PARTICIPATING IN BATEAM PROJECTS 
Agency for I nternational Development 
American Foundation for the Blind 
Association for Retarded Citizens 
Department of Defense 
Department of Transportation 
Environmental Protection Agency 
Food and Drug Administration 
Gerontological Society of America 
National Cancer Institute 
National Children's Eye Care Foundation 
National Eye Institute 
National Heart, Lung, and !3lood Institute 
National Institute on Aging 
National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases 
National I nstitut~ of Child Health and HUman Development 
National I nstitute of Handicapped Research 
National Institute of Neurological and Communicative Disorders and Stroke 
Paralyzed Veterans of America 
Rehabilitation International-USA 
U.s. Coast Guard 
Veterans Aclministration 
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Advisory Design Committee for the Association for Retarded Citizens (ARC). The Western Gerontology 
Society hilS asked Dr. Doris Rouse to serve on their Technology for the Aging Advisory Board this 
year. Other significant travel is described in Appendix A. . 
1 .5 Report Summary 
The Biomedical Applications Team's technical approach to technology transfer in medicine is described 
in Section 2.0. The commercialization of NASA technology is emphasized throughout the team1s 
methodology; that is, the team's activities are divided into four major phases leading logically from 
the identification of opportunities for commercialization to the implementation and monitoring of com-
mercialization strategy. Within each of these four phases, program flexibility allows for technology 
transfer activities related to medical research and institutional technology transfer. 
Section 3.0 summarizes the two commercial transfers completed by the RTI team during the reporting 
period: the Ocular Screening Device, a system that can be used to screen preschool children for 
visual defects, and the Porta-Fib III, a hospital monitoring unit incorporating ·NASA technology in 
vitClI signs monitoring. Two institutional transfers, Implant Materials Testing and Incinerator Monitor-
ing are presented in Section 4.0. In Section 5.0, the results of Phase 0 studies on Mobility Aids for 
the Blind and Ultrasound Diagnosis of Burn Depth are summarized. 
The team's problem solving and transfer activities in active transfer projects are summarized in Sec-
tion 6.0. Projects inactivated during the reporting period are discussed in Section 7.0. 
Section 8.0 is a statement of conclusions and recommendations. This section emphasizes what has been 
learned concerning medical technology transfer and how these lessons can be applied to increase the 
effectiveness of the NASA Biomedical Applications Team program. 
Significant travel is summarized in Appendix A. A summary of the team's project activities for the 
reporting period is presented in Appendix B. Problem statements describing medical requirements for 
improved technology, as identified by the team during the reporting period, are presented in Appen-
dix C. ..
1.6 Definition of Terms 
Biomedical Applications Team--A multidisciplinary group of engineers and scientists engaged in assist.-
ing NASA in achieving widespread utilization of aerospace technology in the medical field. 
Commercial opportunity--The combination of a significant medical need or problem and appropriate, 
relevant NASA technology that constitutes the basis for a potentially successful new or improved com-
mercial medical product. . 
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Commercial technology transferuThe successful development and marketing of a new or improved med-
ical product that incorporates NASA technology. 
Computer information search--A computerized search of NASAls aerospace information bank at one of 
six Industrial Applications Centers (lACs). This information bank consists of more than 1 million 
docum~nts that have been indexed and abstracted in the Scientific and Technical Aerospace Reports 
(STAR) and the International Aerospace Abstracts (IAA). 
Donor--Organization or individual who originally developed technology that is transferred. Within the 
context of the Biomedical Applications Team, NASA is the donor. 
Institutional technology transferuThe application of NASA technology to solve a significant medical 
problem that does not result in a new or improved medical product. 
Medical problem (or need)uA specific and definable technology-related medical problem or need that 
cannot be satisfied by commercially available equipment or by the information available to the problem 
originator through routine information channels. 
Participating jnstitution--A medically oriented educational institution, hospital, medical center, or 
government agency that works with the Biomedical Applications Team in identifying medical problems 
and needs and in evaluating NASA technology that represents solutions to those problems and needs. 
Problem originator--A clinician or medical researcher actively involved in reaching a specific medical 
objective and faced with a specific technology-related problem or need. 
Problem statement--A concise, written description of a medical problem or need that contains sufficient 
details to allow a computer search to be performed and that contains sufficient information to enG)ble 
NASA engineers and scientists to consider possible solutions. 
RecipientsuThe clinical medical sector or medical researcher who uses or applies the technology trans-
ferrec:j. 
RTOP (Research and Technology Objectives and Plans)--A prqposal submitted by a NASA field center 
to NASA Headquarters for funding of research and development proje~ts. 
Technology--AII of the skills, techniques, and understanding that constitute a specific technology. 
Technology includes, but is not limited to, hardware. 
11 
Technology transfer--The movement of a specific technology from one situational context--the one for 
which it was developed--to ~nother. As a resu!t, changes are seen in either the technology or the 
situation to which it is moved or both. 
Transfer agent (or linker)--The individual or orgaflization that plans, stimulates, and facilitates tech-
nology. Within this context, the transfer agent or linker is the Biomedical Applications Team. 
1 .7 References 
1. Public Law No. 85-568, National Aeronautics and Space Act of 1958. 
2. . Haggerty, J. J; Spinoff 1982--An Annual Report. National Aeronautics and Space Administra-
tion, April 1982. 
3. Public Law No. 95-401, National Aeronautics and Space Authorization Act, 1979. 
4. Rouse, D. J. Applications of Aerospace Technology in Biology and Medicine. Research Triangle 
Institute l Research Triangle Park, North Carolina, December 1981. 
5. Rouse, D. J., J. N. Brown, Jr., and R. D. Whitten. Methodology for NASA Technology Trans-
fer in Medicine. Medical Instrumentation, Vol. 15, No.4, pp. 234-236, July-August 1981. 
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2.0 TECHNICAL APPROACH 
The objectives, operations, and methodology of the RTI Biomedical Applications Team are presented in this 
section. The conceptual framework for medical technology transfer described in Section 2.1 provides the 
background and rationale for the Biomedical Applications Team methodology as developed by the Research 
Triangle Institute and presented in Section 2.2. . . 
2.1 Conceptual Framework for Medical Technology Transfer 
A conceptual framework for medical technology transfer is diagrammed in Figure 2.1 The framework 
is basically a bipolar donor-recipient model. The role of the donor, in this case NASA, is to reveal, 
disseminate, and promote technology. The role of the recipient, the medical community, is to seek 
out, evaluate, and utilize technology. 
As explained in the introduction, the primary thrust of the Biomedic~· Applications Team program is 
to transfer technology by the introduction of new and improved medical products. Thus, a manufac-
turer of those products is included in Figure 2. Medical technology transfer normally involves the 
identification of a medical problem or need within the medical community. In response, the National 
Aeronautics and Space Administr(ltion recognizes the relevance of specific aerospace technology and 
makes that technology available. The manufacturer designs, develops, evaluates, and markets a new 
or improved medical product that incorporates aerospa~e technology and represents a solution to the 
medical problem or need. 
The purpose of the transfer agent* in this framework is to plan, stimulate, and facilitate such tech-
nology transfer. This is the role of the Biomedical Applications Team. 
Research into the process of medical technology transfer at the Syracuse University Research Center 
indicates that the donor, recipient, and manufacturer are frequently at cross purposes. 2 The recipi-
ent is concernE;!d primarily with solving a problem. The manufacturer, by necessity, is concerned with 
introducing a commercially successful product. The donor obtains satisfaction as reward for involve-
ment in the transfer process. It is the task of the transfer agent to bring the donor, recipient, and 
manufacturer together in such a way that each views successful technology transfer as. the primary 
objective. A technology transfer methodology based upon an active transfer· agent serving as a 
personal liaison has evolved from the realization that the passive dissemination of information on tech-
nology in itself seldom results in effective technology transfer. This point is illustrated by a quote 
from a Congressional Review of I ntergovernmental Dissemination of Federal Research and Development 
Results. 3 
*The term lliinker il is frequently used in this context. 
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Figure 2. Conceptual Framework for Medical Technology Transfer. 
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The mere availability of information does not cause its transfer or use. Prjnted 
materials alone, even expertly prepared, cannot stimulate interpersonal relations, define 
a problem, answer related questions, involve consulting authorities, provide follow 
through on problems or relate to other agencies. 
The specific role of the Biomedical Applications Team depends upon the motivation, competence, and 
organization of the donor, recipient, and manufact~rer. NASA is highly motivated to transfer aero-
space technology to applications in non-space-related fields. Further, its organization is structured 
to facilitate the development of sophisticated and advanced technology. NASAls understanding of the 
medical industry and clinical medicine, on the other hand, is limited. The technological competence of 
the recipient is varied. Many medical researchers in large medical centers and teaching hospitals are 
technologically competent; the physicians in private practice, in general, lack the facilities and support 
staff required for technological innovation. The manufacturer of medical products may have a long 
and successful history of developing and marketing medical products or may be a small aggressive 
company with innovative ideas but lacking experience or resources for sophisticated device development 
and evaluation. 
The relative importance and role of each participant depends on the technology gap between that par-
ticipant and the technology being transferred. It is the role of the Biomedical Applications Team to 
recognize the strengths and weaknesses of each participant and to supply the motivation, competence, 
and institutional linkages to ensure success. The methodology of the Biomedical Applications Team as 
presented in Section 2.2 addresses these factors. 
Technology will be interpreted throughout this report as including all of the skills, techniques, and 
understanding, as well as the materials, devices, and hardware that make up a specific science. 4 
Technology transfer as used here will refer specifically to horizontal technology transfer; that is, the 
transfer of technology from one situational context--the one for which the technology was developed 
originally--to another situational context. 5 This transfer will normally result in some modification of 
the technology or in the situational context to which it is transferred ~ 
2.2 Biomedical Applications Team Methodology 
As noted in the introduction, and as indicated in Figure 3, the activities of the Biomedical Applications 
Team program are separated into four phases. Within each of these phases, the specific actions and· 
responsibilities of the team are, to a certain extent, fixed. However, team methodology incorporates 
flexibility, which allows the team to respond appropriately to the specific characteristics of particular 
technology transfer cases. Brief descriptions of the methodologies used by the Biomedical Applications 
Team are presen~ed in the following four sections. 
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2.2.1 Identification of Opportunities 
The identification of technology transfer opportunities involves the identification of: (1) a medical 
problem or need, and (2) relevant aerospace technology with the potential to solve the medical problem 
or satisfy the medical need. 
Medical problems are identified through the direct interaction of a team member with a researcher or 
physician within a medical institution. A NASA-funded study of medical technology transfer by the 
National Academy of Engineering concluded that the recipient must take the lead in defining medical 
problems. 6 This conclusion is consistent with the experience of the RTI team. As a result, the 
Biomedical Applications Team emphasizes obtaining complete and extensive qescriptions of medical prob-
lems and needs from the problem origin~tor or recipient. The significance of the medical problem is 
verified by the RTI team through literature reviews and interviews with manufacturers,. health agen-
cies, and other clinicians. 
Certain medical institutions and medical professionals ar~ more innovative than others. 7 Research has 
shown that the first hospitals to adopt innovation usually are large medical centers or teaching hos-
pitals near the sit~ of technology development. Further, those hospitals with highly trained medical 
staff tend to be more innovative. Finally, once a hospital has adopted an innovation, the widespread 
use of that innovation is enhanced if the innovating hospital interacts frequently with other medical 
institutions. The Biomedical Applications Team, in its problem identification activities, has considered 
these factors. 
Because of the innovative physician's emphasis on quality, medical technology introduced in the past 
10 to 20 years has tended to increase the sophistication of medical diagnosis and treatment, but has 
not contributed to a reduction in the cost of health care. The efforts of the Biomedical Applications 
Team have been directed toward the utilization of aerospace technology to requce or contain health 
care costs. 
Technology relevant to medical problems and needs can be identified by a variety of techniques. Once 
a medical problem or need is specified, a computerizeq information search of the aerospace literature 
is ·performed by one of the six NASA Industrial Applications Centers (lACs). The RTI team has used 
the services of the North Carolina Science and Technology Research Center in Research Triangle Park, 
North Carolina. Computerized information searches can identify information on potentially relevant 
technologies. 
An additional approach to identifying aerospace technology is the circulation of problem statements to 
NASA field centers. Individual medical problems are concisely described in problem statements. At 
each center, a technology utilization officer, who is responsible for the management of technology 
transfer activities at that facility, distributes the problem description to the appropriate scientists and 
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engineers for review. Responses to problem statements from these engineers and scientists can lead 
to the identification of solutions based on NASA technology. 
Finally, the Biomedical Applications Team contacts NASA personnel known to have a strong interest in 
transferring technology to medicine and known to be working in relevant technical areas. This is the 
most direct, efficient, and rapid approach to finding technology. The next phase of the program is 
the investigation of factors that determine which opportunities ar~ most likely to be successful. 
2.2.2 Screening 
Effective screening enables the RTI Biomedical Applications Team to focus on those opportunities with 
the most promise for successful medical solutions and commercial products. To continue work on a 
particular opportunity, the team must determine that most of the following requirements are satisfied: 
The solution improves medical treatment or diagnosis or reduces th~ cost of health care. 
The solution is recognized by a Federal health agency and the medical community as a 
contribution to improved health care. 
The solution incorporates NASA technology or expertise. 
The market for the n~w qr improved medical product justifies the required capital in-
vestment and production cost to the manufacturer. 
A manufacturer can be offered sufficient market protection, either by exclusive license 
or by lead time, to justify the required investment in product development. 
The s01ution represents a discrete, well-defined transfer of technology involving limited 
research and development effort. 
Candidate manufacturers with the required marketing and production capabilities have 
expressed an interest in commercialization. 
These factors are evaluated by review of the biomedical literature, market surveys, interviews with 
industry representatives, and discussions with appropriate medical staff. Much of the data collected 
in this process is used in the development of commercialization strategies as described in the next 
section. . 
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2.2.3 Commercialization Strategies 
The development of strategy for successful technology transfer must consider product development and 
marketing, clinical trials, FDA approval, acceptance by the medical profession, and identification of 
funding sources for the various tasks involved. Because of the emphasis on commercialization of NASA 
technology, strategies must involve obtaining industry participation. 
The National Academy of Engineering study of medical technology transfer referenced in the preceding 
section reached some important conclusions concerning strategy for technology transfer. 6 Successful 
technology transfer requires significant involvement of the donor and recipient throughout the transfer" 
process. Further, the involvement of industry throughout the transfer process is essential. The 
manner in which new technology is introduced to the medical field is a critical factor in successful 
technology transfer; the new or improved product must be accepted by and applied by the" medical 
community. 
The medical technology transfer model in Figure 4 was developed by the RTI team to summarize the 
requirements for each phase of this complex commercialization process. An important lesson that can 
be taken from this model and the team's experience is that careful planning throughout the project is 
necessary for successful product development and transfer to industry. 
The experience of the RTI Biomedical Applications Team has confirmed and expanded these conclusions. 
Industry must be involved throughout the transfer process and must be included as early as possible. 
Further, the involvement of industry generally requires some means for giving a specific manufacturer 
a proprietary position. This may involve either an exclusive license to a patent or lead time to allow 
sudden entry of the new product into the medical market. I ndustry tends to view new product oppor-
tunities from the outside as competition with its own internally generated product ideas, which means 
that opportunities for technology transfer generated through the NASA Technology Utilization Program 
have to compete for industry capital and management attention. These barriers can best be overcome 
by the Biomedical Applications Team through an analysis of patent positions, development costs, and 
market studies, followed by careful selection of potential manufacturers. 
The acceptance of a new product by the medical community involves a fairly specific sequence of 
events. The product must be subjected to clinical trials and the results published by a recognized 
medical expert. Additionally, the product usually must be exhibited at medical meetings. 
Medical marketing and distribution are not necessarily an integral function of all medical product manu-
facturing firms. Thus, in addition to obtaining the participation of a medical product manufacturer, 
the team may also need to identify and involve an organization capable of marketing and distributing 
those products. 
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Each specific opportunity for medical technology transfer offers a new set of barriers and strategic 
options. Thus, the formation of strategy is not a specific activity; it is a problem-solving effort. 
The most important common feature of strategy formation is thoroughness; all contingencies must be 
anticipated. 
2.2:4 Implementation and Monitoring 
Experience in implementing strategy has shown that the chance for successful technology transfer is 
increased by ~ctive involvement of the Biomedical Applications Team throughout the transfer process. 
By monitoring and coordinating the activities of the participants, minor problems can be prevented 
from becoming major obstacles. The RTI team prepares Gantt charts and Project Evaluation and 
Review Technique/Critical Path Method (PERT /CPM) scheduling networks to provide systematic analysis 
for complex projects. These chaets, which aOre too large to be includeq in this report, are sent to 
the participating NASA field centers and to NASA Headquarters. 
Documentation is an integral part of the team methodology; it is required throughout the technology 
transfer process. Implementation of strategy is no exception. Periodic status reports are issued 
informally to keep all participants informed. Upon completion of the transfer process, the team 
prepares a technology transfer report documenting all important aspects of the transfer process. 
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3.0 COMMERCIAL TRANSFERS 
3.1 The Ocular Screening Device 
The ocular screening project at Marshall Space Flight Center (MSFC) has resulted in the development 
of a commercially available optics system that can be used to assay the visual acuity of large numbers 
of persons quickly by means of color photography of the retinal (red) reflex of the eye. Electro-
Optics Consultants (EOC), Inc., of Huntsville, Alabama, is responsible for manufacturing and market-
ing the system, called GRRIS-Model IV (generated retinal reflex Imagery ~ystem). This device is 
especially useful for screening the vision of preschool children for defects. The performance of GRRIS 
has been evaluated in two screening projects and by a scientist at the Smith-Kettlewell Eye Research 
Foundation of San Francisco, California. Controlled tests were designed, performed, and evaluated 
by the scientist to determine the system's sensitivity and accuracy in revealing visual defects in pre-
school children and in infants. 
The project has involved the cooperative efforts of the following organizations and persons: NASA 
Marshall Space Flight Center; S. Hutson Hay, M.D.; Joe Kerr, Ph.D., President of EOC, Inc.; the 
Alabama School for the Deaf at Talladega, the Lions Club of Huntsville; the National Children's Eye 
Care Foundation; and the Research Triangle Institute's NASA Biomedical Applications Team. 
3.1.1 Background 
Visual defects in preschool children can develop into permanent disabilities. For example, if amblyopia 
(1Ilazy eye") is allowed to persist for several years before a child reaches school age, the visual path-
ways to the brain fail to develop properly. What might have been only a minor visual defect can 
result in permanent loss of vision in one eye if the condition is not detected promptly. Other condi-
tions such as cross-eye, myopia, and hyperopia can occur in early childhood and remain undetected, 
to the 'detriment of the child's mental and physical development. Ideally, each child should receive an 
eye exam at age three and another by age six. However, suitable eye exams are not usually obtained 
due to children's lack of communication skills- and short attention span and parents' unawareness of 
the necessity for testing. 
3.1.2 Development and Commercialization of GRRIS 
Dr.' Hay, an ophthalmic surgeon in Huntsville, Alabama, developed the concept of using the retinal 
reflex to screen the visual acuity of large numbers of preschool children. The reflex is the red light 
that is reflected from the back of the human eye. The reflex can be photographed by piacing a 
camera and a flash unit very close together and inducing the subject to look directly at the camera 
lens from a distance of 5 to 12 feet. A collaborative project was established between NASA MSFC 
engineers, Dr. Hay, and Electro-Optics Consultants, Inc. The objective of this project was to design 
and fabricate a photographic system for recording and analyzing the retinal reflex and an analyzer 
for automatically evaluating the photos after development. 
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Several' evaluations of the GRRIS system have been conducted. At the Alabama School for the Deaf, 
in· Talladega,. Alabama, .. 450 students were screened by. the GRRIS system. Those students. whose 
GRRfS~ photos. were suspect' were: examined. by' volunteer staff of the University of Alabama· Medical 
School at Birmingham~ Theceye exams corroborated:the·GRRIS evaluation of possible visual defects. 
In a second. evaluation project initiated to obtain data representative of the general population, the 
Lions Club of Huntsville volunteered to do the GRRIS photography at regional kindergartens. The 
parents of. each child~ with a. suspect GRRIS photo were advised by postcard to seek a professional eye 
exam for the child. Financial support for the Huntsville screening project came from the National 
Children's Eye Care. Foundation,. Washington, DC. The Lions Club is considering the expansion of 
this screening~ project to other cities within Alabama. Thus, the concept of retinal reflex screening 
may, become statewide,. or even nationwide; 
A scientific evaluation of the GRRIS system took pl~ce during a 5-month period in 1982 at the Smith-
Kettlewell: Eye. Research Foundation in San Francisco. Their evaluation verified an 88 percent positive 
correlation of GR R IS· images. in' the identification of. all visual defects. The system's performance was 
excellent in tagging major' visual, defects· within the' range of ±0.25 to 10 diopters but was less precise 
in the identification of visual defects. within the +0.25 to -0.25 diopter range; i.e., very close to 
normal vision. The GRRIS system correctly flagged. visual defects in several 4-month old infants, thus 
demonstrating, its potential in testing the vision of this nonverbal sector of the population. These 
successful evaluations have: been. useful to EOC in their marketing of the system. 
3·~1.3. Description of theGRRIS 
The GRRIS is: 8-' portable photographic system that can be transported by auto and set up quickly at 
schools and: other public sites. The system consists of two components horizontally spaced. approxi-
mately 12 feet apart. One' component is a· screen through which the subject's eyes are visible to the 
remote, camera, and: flash unit. The screen serves to position the subject's eyes exactly at the' object 
focus; plane" of the. camera, lens.. The'second component of the system is the camera and; flash assembly. 
The flash, assembly is. placed' adjacent to the camera. lens so that the full extent of the eye's retrore-
flection· (reflex) wilh be' viewed. by the 400-mm camera lens. A bright, blinking, light-emitting diode 
is .. placed:at the'rim of the'cameradenstodraw the subject's eyes directly toward the camera lens. 
The subjects. approach the GRRIS after waiting for several minutes within the dimly lit room. Thus, 
the subject's pupils are naturally dilated, allowing maximum flash illumination to enter the eye and 
maximum. reflex to, exit toward' the camera:. The actual photography of the GRRIS takes only seconds. 
Five' to: six children, can be- photographed within a minute's time depending on the ability of the child,. 
ren to: follow verbal! instructions. Any adult can operate the GRRIS system with only brief instruc-
tion. 
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The GRRIS photographs are developed by conventional color slide processing. In a typical kinder-
garten population, 75 percent of the slides will show normal eyes. These children are eliminated at 
the initial evaluation. The remaining 25 percent are reviewed more carefully and perhaps 3 to 10 per-
cent of these are judged to be normal. The remaining slides exhibit nontypical retinal reflexes, caused 
by any of several visual defects. 
3.1.4 Summary of the GRRIS Project 
Objective 
To design, fabricate, and evaluate a portable photographic system for documenting the retinal reflex 
from human eyes as a means of screening the visual acuity of preschool children. 
Project Summary 
May 1979 
May 1979 
May 1980 
November 1980 
February 1982 
December 1982 
December 1982 
RTI team member Dr. Richard Scearce attended a presentation at MSFC during which 
the concept of vision screening of preschool children was brought to the attention of 
the MSFC Technology Utilization Office staff. 
Clark Beall of the RTI team traveled to MSFC to consult with the Technology Utiliza-
tion Office staff in preparation for the NASA RTOP to fund the development of the 
GRRIS. 
I nitial arrangement was made with the Alabama School for the Deaf to use the proto-
type GRRIS device to screen the vision of 450 students. 
Clark Beall visited MSFC and reported to NASA Headquarters the physiological and 
technical basis of the GRRIS. 
Initial arrangements were made with Smith-Kettlewell Eye Research Foundation to test 
the GRRIS device from May to September 1982. 
Clark Beall attended the presentation of the test results by Anthony Norcia of Smith-
Kettlewell at MSFC. 
EOC, Inc., is marketing production models of the GRRIS based on the two field tests 
and the Smith-Kettlewell evaluation .. 
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Portable Medical Status and Treatment System and the Porta-Fib III 
Th~·pprt~J?.l.e· Meqi~.~1 Sta~.us .~r~p Trea~~en~ Syst~m (PrtlSTS) and the Por~~-Fib III are spinoffs of .a 
N~~A- prpj~.ct !<I')()wn ~s fh~ PJ1y~.iciqn's Blqck Bag, ~ portabte monitoring and treatment system devel-
oped by Tel~~C:Jre, Inc., .a ~ompa.ny I~~er acq!Jir.ed by Narco S<:i~n~ific. The PMSTS was designed as 
~n emergen~y care sy~~em fpr us~ jn r~,mote areas wher~ treatment at a hospital may be delayed. 
T,he porta-Fip III ( cleyelpPli:!p PY N~r<:o S<:iEmtific Bio-Systerns Division, Hpuston, Texas, is a companion 
system to the RfV!?T? d.esign~(f for LJse in tl"!e ho.spital. Both the PMSTS and the Porta-Fib III utilize 
I'-JASA tech!lplogy in a:;~r()n~!Jt monitpring I electronic circuitry, and microminiaturization. The RTI 
team's rple in the prgject il1c1lJped interviews with physicians to determine the features required in 
the device ,and to estimCite th~ rni3rl<.et. To iclefltify potential applications and markets for the PMSTS, 
the RT I ~~!:im gi~<:u~~ed the syste!Jl with the U. S. State Department Office of I nternational Health and 
~he p!=!ac~ ~()rps tp expJor~ !J~~ of the system in deve'oping countries. Dist:ussions with the Depart-
m,ent of TrclnsporHtipfl an~ ~h~ ~ ~ S. Coa~1: GLJard' r~s!Jlt~c:t in sppnsorship of field tests by both of 
~he~~ ~rQClniiZClti()ns. 
3.2.1 Portable Medical Status and Treatment System 
The prtl?TS i? a port()!JI~'PClttery-pow!=!r!=!q !Jnit that 1l1cl!Jdes a vital signs monitor, a defibrillator, 
~nd a !.JHF trClnsc~iver fqr tra.ns.missi~m of information to hospital staff. The microprocessor-based 
monitor jn<:l!-:Icle~ ~ cI~ta r~c:prgE:!r Clnd scope, an electrocardiogram monitor, and respiration, tempera-
t!-lr~, Clnci p!ppp pr~ss!Jr~ mpnitprs and alarms. A schematic of the vjta.1 signs monifor controls anq 
indica!ors is s,twwn !n FigHr~ §~ The :;!=ope sirnul~aneoLJsly displays the electrocardiogram, heart rate, 
respip:ltiPfl r9te, te!11p~ratHr~, a.nq blopd pressure. 
The cI~fi~rilla.t()r pgrtlpfl pf lh~ Pry'lST? is !-Ise~ to qeliver an el!=ctric charge through the chest to the 
he~rt t() restpr!= a rhythrT)ic \leart peat. Defibrillation is neE:!ded when an erratic heartbeat is ineffec-
ri¥~ in e~rnping ~!g()cI tp th~ PPHY· Th!= PM?TS a.1I()ws the s!=lectipn of six different charge levels for 
the cI~fiRri!'atip'n pa~RI~~. .... . 
The PIY1?T? tra.nsc~jver is a. 1 O~chClrlnel rCidio with two-way voice communication. This radio system 
~lIpws rra.nsmis,sipn of the pa.ti~nt'~ vi~C11 signs to a hospital ancj the r~lay of instructions to the 
~tt!=nqC1nt ~ith th~ p~ti~llt. 
TW!=l Pty!~TS ~nits wE:!re ~valu~ted by the Department of Transportation. One unit was used in the 
First ~e~ponqer Prpgra.m In Indi~na County, Pennsylyania. In this program, emergency medical tech-
ni~l?n vql~.mteers p'r()yipe if11llleqi~te medi~al care in rural areas. The secpnd PMSTS was evaluated by 
th~ CPCl~t G\-Iclrq h~licopter r~sq-!e crew in Clearwater, Florida. In this application, the PMSTS was 
~sed tp provlq~ efr1~rgel1cy !l1eqjq:t1 care anc:i monitoring en route to a m~dical facility. In the helicop-
ter eY¥1I~C1tion, th!= ampient I')oi~e int~rfered with the blood pressure measurement and alarm detection. 
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Figure 5. Vital Signs Monitor Controls. 
3 ... 2.2 Porta-fib III 
An analysis of the market resuJteci. in a decision by Narco Scientific to commercialize the vital signs 
monitor technology in the PMSTS, as part of a hospital monitoring unit. The two-way radio portion of 
the PMSTS was not required in the hospital environment. The vital signs monitor was combined with 
existing; systems for defibrillation and display in the Porta-fib III. 
Narco Scientific Bio-Systems Division. has built the first twenty Porta-Fib III units. Expanded proquc-
tion and marketing are expected by June of this year. . 
3.2.3 Summary of the. PMSTS and. the Porta-Fib III 
Project Summary, 
August 1915, New Technology Transmittal on Physician1s IIBlack Bag ll submitted by Telecare, Inc., 
on, NASA Contract NAS9-14334 .. 
January 1979 
March. 1980 
NARCO Scientific, Inc., purchasecl Telecare, Inc. Narco will continue the PMSTS 
worl< with NASA .. 
The RTI team completed a study on the commercialization potential for the PMSTS. 
September 1980 The RTI team participated in a Final Design Review for the PMSTS at Narco Biosys-
terns in Houston ,. Texas. 
March 1981 Two PMSTS units delivered to Department of Transportation for evaluation in rural 
emergency' medicine and a Coast Guard Rescue helicopter. 
June 1981 Narco Bjo~Systems incorporated the PMSTS vital signs monitor into a hospital monitor-
ing unit to be called the Porta-Fib III. . 
February 1983 Twenty Porta""fib III units incorporating the NASA PMSTS technology have been built 
by Narco Biosystems. Expanded production and marketing activities planned for 
1983. 
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4.0 INSTITUTIONAL TRANSFERS 
4.1 Implant Materials Testing 
Many design and fabrication aspects of metallic surgical implants result in local regions of high stress 
where defects exist or develop during use. Current screening methods for these devices do not eval-
uate the effect of these factors. The need to improve the reliability and performance of metallic 
prosthetic devices is well documented. 1 2 3 
Aerospace material evall!ation procedures have shown that screening tests using smooth samples with-
out simulation of stress concentrations or sharp flaws can give misleading resl!lts. Flujd environments 
may not initiate flaws, but will drastically increase the growth rate of any preexisting flaws. Frac-
ture control methods (material qualification, design, and inspection) developed by NASA for screening 
critical spacecraft hardware could be applied to metallic implants. NASA's procedures for evaluating 
the impact of a liquid environment on mechanical reliability would be especially applicable. 
In July 1980, the RTI team met with Edward Mueller, Don Marlowe, and Daniel Chwirut from the 
Bureau of Medical Devices, Food and Drug Administration (FDA), to discuss the application of Johnson 
Space Center fracture control methods to metallic implants. It was agreec;:l in that meeting that NASA 
and FDA should support a program to transfer this NASA technology to prosthetic device fabrication 
and testing. Eagle Engineering, Inc., an aerospace fracture control company, was selected as the 
contractor for this task. 
Eagle Engineering completed a $19,000 feasibility study for NASA Langley Research Center in June 
1981. Following a favorable review of the results, the FDA transferred funds to Langley Research 
Center for a 2";'year continuation of the study to improve implant design and testing. As a result, 
Eagle Engineering has completed a handbook for medical device manufacturers on fracture control 
aspects of the six most common metal alloys used in implanted prostheses. 
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4.2 Incinerator Monitoring 
The incineration of municipal refuse is a developing technology that both disposes of wastes and pro-
vides energy. Smokestack monitoring is necessary to ensure complete combustion and to prevent the 
production of noxious fumes and gases. Therefore, a continuous, on-line monitoring system is needed 
for the immediate cietection and correction of defective combustion. 
Mass spectrometry is an important instrument in the detection of combustion products. The mass 
spectrometer is capable of differentiating between organic compounds with very similar structures and 
molecular weights. The General Instrumentation Branch at Langley Research Center has an active 
program in quadrupole mass spectrometry research and development. 
In March 1982, the RTI team first discussed NASA's mass spectrometry technology with Merrill Jackson 
at the U.S. Environmental Protection Agency (EPA) laboratories at ~esearch Triangle Park, NC. 
The EPA is interested in a mass spectrometer because it is sensitive enough to monitor all emission 
products of interest and is portable enough to be mounted in a van. An instrument of this type is 
especially needed to monitor a new hazardous waste incinerator under construction near Boston, 
Massachusetts. 
As a result of EPA's interest during the initial discussions, the RTI team coordinated a meeting at the 
EPA research facility at Research Triangle Park on April 29, 1982, of EPA personnel and NASA scien-
tists from Langley Research Center. The objective of the meeting was to discuss the applicability of 
the NASA quadrupole mass spectrometer for monitoring smokestack emissions. In a followup meeting 
at Langley in May 1982, Dr. George Wood, Jr., demonstrated the operation of the NASA instrument. 
On the basis of these meetings, EPA has committed funds to obtain a NASA-Langley quadrupole mass 
spectrometer by a contract to Analog Technology Corporation. The EPA researchers will be trained 
in the use of the instrument by Dr. Wood and other Langley researchers. 
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5.0 PHASE 0 STUDIES 
5.1 Mobility Aids for the Blind 
5.1.1 Introduction 
An important priority in research relating to blindness and low vision is the development of improved 
methods for safe mobility. Recognizing this need, the Veterans Adlllinistration(VA) requested that 
NASA Ames Research Center collaborate with the VA Rehabilitation Research and Development Center 
in Palo Alto, California, to develop an improved mobility aide for the blinq. NASA Headquarters 
requested that the RTI team assist NASA-Ames and the VA in a Phase 0 study to establish the 
requirements and examine the feasibility of a new mobility aid for the blind. To ensure close coordi-
natiol1 between the organizations, RTI supported SR lis participation in the project as an RTI team 
consultant. The Phase 0 study results are summarized in this s~ction. 
5.1.2 Problem Definition 
Approximately 11.5 million persons in the United States suffer some degree of visual impairment. 
Twelve percent are unable to s~e well enough to read newsprint; four· percent ·are classified as legally 
blind.! 
Approximately 47,000 people become legally I:>lind each year in the United States. There are 397,000 
severely impaired and legally blind persons in the United States under the age of 65. The distribu-
tion of new cases of legal blindness by age and sex is shown in Figure 6. According to the American 
Foundation for the' Blind, approximately 20,000 visually handicapped persons are trained by mobility 
and orientation specialists each year. 
Audition is an important sense for safe mobility of the visually impaired. Hearing, like sight, can 
provide information about the environment beyond the individual's reach. In addition to obvious 
environment identification through hearing, the visually impaired can use reflected sound to avoid 
obstacles. For instance, a visually impaired person can determine when he has reached the end of a 
hallway by the relative absence of reflected sound. This dependence of the visually impaired on 
subtle sound discrimination for safe mobility mus.t be considered in the design of a new mOl:>ility aid. 
5.1.3 Mobility Aids in Use 
The four most common mobility aids used by visually impaired persons are sighted human guides, 
canes, guide dogs, and electronic travel aids. 
A sighted human guides the blind person by walking by his side and providing verbal instructions 
and/or a leading arm. Human aids assist in all mobility tasks and provide companionship. Human 
guides, however, are not always available and are expensive if the service is purchased. 
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A guide dog is trained to understand commands, avoid obstructions, and recognize potentially dan-
gerous situations. The dog wears a harness that is held by the visually impaired person. Dogs 
usually provide reliable guiding and companionship for the user. Major disadvantages of guide dogs 
are the expense of extensive training and a relatively short lifetime of approximately 10 years. 
Canes are the most common mobility aid used by the visually impaired. The types of canes available 
include the long cane, a folding or collapsible cane, and an orthopedic cane. These canes are fabri-
cated from wood, aluminum alloy, fiberglass, plastic, and stainless steel. The cane extends the tactile 
sense of the USer to provide information about the environment. The cane can inform the user about 
ground surface textures, downsteps or slopes, and obstacles. The cane thus protects the lower body 
from collision. 
The cane is reliable, requires little maintenance, and is unaffected by adverse weather conditions. 
The major disadvantages of the cane are that it does not provide adequate protection against collision 
to the upper body and the range of information available to the user is limited by the length of the 
cane. In addition, extensive training is required for effective use of a cane for mobility. 2 
An electronic travel aid (ETA) is a device that emits signals to sense the environment, processes the 
information received, and furnishes the user with information about the envlronment. An ETA should 
warn the user of obstacles in the travel path from the ground to the head and should warn the user 
of any surface discontinuities that could represent a safety hazard. Advantages of the ETA over the 
cane are the extenqed detection range and ability to scan the environment allowing a better under-
standing of the envir'onment and more accurate location of objects. Disadvantages of some ETAs are 
frequent repairs, replacement or recharging of power source, interference with natural sensory 
channels conveying information about the environment, and appearance that is cosmetically unaccept-
able to the user. 
5.1.4 Electronic Travel Aids Available 
Most electronic travel aids transmit an ultrasound or optical energy wave, which is reflected from 
objects in the traveler1s path. The ETA then decodes the signal and displays the information to the 
traveler. The display is usually tactile or auditory. Optical transmission is used where range 
determination is not a specification for the device. Ultrasound systems offer excellent distance resolu-
tion, scanning beams from 5° to 90° in width, and the availability of cosmetically acceptable transducer 
sizes. 3 
The Russell Pathsounder was one of the first ultrasound ETAs. As shown in Figure 7, it is suspended 
from the neck, providing a 30° scanning be~m. The Pathsounder is an obstacle detector with a6-foot 
range and some range estimation capability. The output to the traveler may be tactile or auditory. 
With the auditory option, if an object is within 3 to 6 feet, the Pathsourider emits a low-pitched buzz; 
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a higher pitched tone warns that an object is within 3 feet. A significant advantage of the Path-
sounder is the simplicity of the two-tone output, which makes it easy to learn. This device is often 
used to help' the young visually impaired become familiar with ETAs in preparation for more complex 
devices in the future. The disadvantage of the Pathsounder is th~ limited information provided to the 
user on the environment. 
The Mowat Sensor is a hand-h~ld ultrasound device with a vibration output to the user. The proximity 
of the user to an object is indicated by the vibration frequency. The user may select the short range 
to detect objects within 1 meter or the longer range to detect objects as far away as 4 meters. The 
Mowat Sensor is designed for use with a cane or guide dog to extend the range of detection with a 
noncontact system. It is lightweight and relatively inexpensive. The major disadvantage is that when 
it is used with a cane pr guide dog, both hands are occupied. 
The laser cane is a long cane with three infrared light emitters aimed to detect obstacles at three 
levels: head, waist, and ground. The output for the laser cane may be tactile or auditory. 3 The 
user may select a 6- or 12-foot range for detection. The laser cane can help the user find an 
obstacle-free path and detect d~op-offs. By moving the cane from side to' side, the user can 
determine the width of an object or detect an open doorway. A major disadvantage of the laser cane 
is that the cane1s beams fail to register the presence of a plate glass window. 
The binaural sonic aid, sold commercially as the Sonicguide ™ uses a wide' angle (60°-90°) ultrasonic 
transmitter and two receiver channels mounted in a pair of eyeglasses. 3 The receiver channels are 
presented to the left and right ears. The electronics and the batteries are in a small box that hangs 
at the user's side. An object on the user1s right side will result in a louder sound to the right ear. 
With this stereophonic presentation and appropriate training, the user can detect an o~ject's direction. 
The distance of the object is indicated by pitch. The range of the Sonicguide ™ is 0 to 15 feet and 
30° to each side of center. 4 
Although the Sonicguide ™ provides more information about the environment than other ETAs, it is 
not a primary mobility aid and must be used with a cane or guide dog. The Sonicguide ™ cannot be 
used as a primary mobility aid because it cannot detect drop-offs such as steps or curbs. The major 
disadvantage of the Sonicguide ™ is the extensive training required to interpret the information pre-
sented to the user. 4 
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Other -electronic travel aids currently under development are : 
Computerized Travel Aid : American Foundation for the Blind . The CTA is an ultra-
sound .system that includes.a ;microprocessor for calculation of distance information 
before presentation ,to the user . 
. Infrared Ranging Systems: Smith-Kettlewell Institute. This system is a hand-held 
device for intermittent use with a guide dog or cane. The technology in this inexpen-
sive system was developed by Honeywell, Inc., for use in auto-focusing cameras. 
Monaur.al Version of the Binaural Sonic Guide: University of Canterbury, New Zealand. 
This system uses a narrow-beam, single-channel FM sonar system. 3 This system 
decreases the training necessary for the binaural system. 
5.1.5 NASA Concepts ,for Electronic Travel Aids 
,Following ,a review of the advantages and disadvantages of current mobility aids, the following re-
searchers suggested concepts for new devices for consideration in the Phase 0 study. 
• Tak.Matsumoto 
,Electronic Engineer, NASA Ames Hesearch Center 
Cesar Mina 
Electronic Technician, NASA Ames Research Center 
Nikki Velkoff 
Engineerin.g .Associate, NASA Ames Research Center 
. Sally 'Wood 
:BiomedicaIResearchEngineer, VA Rehabilitation Research and Development Center, Palo 
Alto ,Cal ifornia. . 
Several ,of these concepts are described in the following subsections. 
The Video Vision Mobility Aid is designed to help a blind person travel down the middle of a side-
walk. The ·middle is the safest because most obstructions either on or overhanging the sidewalk are 
,usually:atthesides. This would .alsoassist the blind traveler in walking a straight path. 
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The concept for this mobility aid is a video camera that would point at the sidewalk ahead. The video 
data would then be processed to detect and enhance edges. All data that did not conform approxi-
mately to the preconceived image of the sidewalk edges would be eliminated. This type of "intelligent" 
system is widely used in lndustry and has been well documented. The output of this device would 
most likely be tactile, and would include directions to move and/or turn to the right or left. The area 
of information transfer to the user is not trivial and would require a concerted effort by NASA and 
the VA. 
This aid is perceived as high technology with long-range goals and is not considered an instant solu-
tion to a multifaceted problem. A working prototype is perceived within 2 years for evaluation. 
The Obstacle Detector will probably use an ultrasonic transducer to detect obstacles from waist high 
to slightly above the head. The sensitive distance ahead of the user would probably extend farther 
than 6 feet. This device is perceived as being disguised as a pair of spectacles, which would allow 
scanning by turning of the head. The output· would be tactile and indicate the presence and range 
of the obstacle. The most difficult problem foreseen is the design of a suitable ultrasonic transducer. 
Currently popular transducers such as the Polaroid unit emit field patterns unsuitable for this appli-
cation and are too large. The availability of a newly developed piezoelectric plastic filter appears 
promising as the basis for transducer research. 
The Person Detector determines the location of people primarily in social situations but it would also 
allow a blind person to detect the presence of someone in a room. A thermopile, which is sensitive to 
infrared radiation, is proposed as the sensor. A thermopile with a field of view of 90° has been tested 
and appears to be sensitive enough to detect a human at 3 feet. A miniature lens has been proposed 
for use to decrease the field of view to 30° and increase the aperture, thereby increasing the range 
beyond 3 feet. The sensor would work best located on the head of the user to allow scanning by 
turning the head. The output is proposed to be tactile. The type and amount of information to be 
transmitted to the user has yet to be determined. 
The impetus for developing a Compass for the Blind originated as a request from the Western Blind 
Rehabilitation· Center for a device that would help a blind person walk in a straight path where there 
is no environmental reference. A rough estimate of device sensitivity indicated that a device would 
have to be accurate to ±0.2° in order to control a person within ±2° of a straight line. Mounting a 
device of this accuracy on a person would probably be impractical; however, a device that is accurate 
to ±5° might be feasible. Such a device is pictured as a single-axis magnetometer to indicate direc-
tion. An additional device would be required to indicate how level the magnetometer is in order to 
obtain the directional accuracy. Single processing would be necessary to correct for tilt and to calcu-
late the direction to which the person is pointing. It is possible that a much higher directional 
accuracy than ±5° can be obtained. A microprocessor would be necessary for the signal processing. 
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'5.1.6 Completion of the Phase 0 Study 
The Phase .0 study .on .mobility .aids.for the blind .,will .be completed by ,May 1983. The RTI team will 
,continue to .~ssist NASA Ames and ·the ,VA ·facility .in Palo Alto in that effort under funding :from NASA 
,Langley·:ContractNASI717214. The.tasks r.emaining .in the study are: 
Selection of thecQncept .mostappropriate for development by NASA and the ..vA. 
Identificati(m of ·.NASA technology used lin the ,proposed travel aid. 
Preparation of a project ,plan .for ·refinement ·of the concept, hardware development, 
.evaluation ,and commercialization.' .. 
.' Definition of theacti,vities .for the participating organizations, method for $electing the 
rn~n.uf~ctur.ers, and cofllr.lQiogcornmittments,for the project. 
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5.2 Ultrasound Diagnosis of Burn Depth 
5.2.1 Introduction 
Early and accurate determination of the depth of a nonsuperficial burn is critical for the optimal man-
agement of burn patients. Dr. John H. Cantrell, Jr., a physicist at Langley Research Center, devel-
oped a concept for determination of skin burn depth using ultrasound. This concept is based on the 
observation that the acoustical impedances of burned dermis, viable dermis, and subcutaneous fat 
differ sufficiently to detect the inte~face between burned tissue and the underlying unburned tissue. 
This rapid technique for burn depth determination could facilitate early excision of full-thickness 
burns and thus reduce mortality and lead to a more rapid and complete rehabilitation of the patient. 
John Samos,_ Technology Utilization Officer, NASA Langley Research Center, requested the RTI team's 
assistance in a Phase 0 study on the proposed ultrasound burn diagnosis system. The results of this 
study are summarized in this section. 
5.2.2 Problem Definition 
Approximately 2 million Americans suffer serious burns each year, and 200 to 300 thousand of these 
people require hospitalization. Among those- hospitalized, 70 thousand receive intensive care and 10 
to 12 thousand die. The cost of intensive care exceeds $300 million per year. l Clearly, these statis-
tics indicate the potential impact of improvements in the prevention and treatment of burn injuries. 
5.2.3 Burn Wound Classification 
Burns of the skin are classified according to depth as first, second, or third degree as indicated in 
Figure 8. Because burn depth is critical to wound care and mortality, determination of the degree of 
injury'is important for planning therapy and anticipat,ng patient requirements. 
First-degree burns involve only the epidermis or superficial layer of skin. Healing will occur within 
5 to 10 days with no scar formation. 
Second-degree burns involve all of the epidermis and extend into the dermis. In superficial second-
degree burns, healing occurs within 2 weeks. Deep second':degree burns usually require 4 weeks or 
more. 
Third-degree burns result in destruction of the entire epidermis and dermis. Subcutaneous fat, 
muscle, and even bone may be affected. Extensive third-degree wounds will not heal in a timely 
fashion and must be grafted to achieve wound ctosure. Accurate and early differentiation between 
deep second-degree and_ third-degree burns is important to the surgeon for determining the extent to 
which grafting will be required. The new nomenclature suggested for classification of burn ~ounds is 
presented in Table 5. 
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TABLE 5. OLD AND NEW BURN CLASSIFICATION29 
Nomenclature (new) 
Superficial 
Partial thickness 
Full thickness 
Definition Nomenclature (old) 
Epidermis only First degree 
Epidermis and dermis at varying depths Second degree 
Epidermis, dermis, and appendages 
Degree 
[ I 
- Deep 
/ Third Degree 
® 
Source: Treatment of Burns. Yang Chih·chun, Hsu Wei·shia, 
and Shih Tsi-siang, eds. Springer Verlag, New York, 1982. 
Figure 8. Classification of Depth of Burn. 
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Epidermis 
Dermis 
Subcutaneous 
Tissue 
Third degree 
5.2.4 Burn Wound Treatment 
Modern treatment of burn victims is based on early recognition, removal, and grafting of full-thicknet)s 
Injuries. Not only is the risk of infection minimized by this aggressive procedure,2 but healing is 
hastened and dermis that otherwise would be lost to progressive necrosis may be saved. The tech-
niques used for early removal of dead tissue include excision down to the fascia,3 sequential or 
IItangential li excision to viable tissue in deep partial-thickness burns and certain full-thickness 
burns,4 5 and chemical debridement. 6 For burns that present an obvious picture of full-thickness 
loss, the surgeon can begin excision or chemical debridement in the regions of greatest injury and 
appropriately extend the area of removal by noting characteristic bleeding patterns of viable fat and 
dermis. Unfortunately, depth of injury is difficult to diagnose except in extreme cases of tissue 
destruction. Clinical judgments based on surface appearance and sensation to pinprick or hair removal 
are unreliable and imprecise. Thus, areas of full-thickness injury can masquerade as areas of partial-
thickness injury, and vice versa. The resulting erroneous diagnosis either eliminates the advantages 
of early removal or causes the sacrifice of tissue that would otherwise heal itself with better function 
and cosmesis. 7 
5.2.5 Current Methods for Burn Depth Determination 
Although judgments based on surface appearance and sensation to noxious stimuli provide quick infor-
mation on the general nature of the burn wound, many investigators have emphasized that these judg-
ments do not necessarily reflect the true depth of injury. 8 15 The problem in evaluating surface 
appearance or discoloration is the lack of a direct relationship between the severity of surface burning 
. and the depth of burn injury. For example, burning at the surface depends primarily on temperature, 
but the depth of injury depends both on temperature and duration of exposure. Burns of grossly 
different depths can have similar appearances when viewed from the surface. A host of factors other 
than temperature can affect surface appearance. These factors include the burning agent, the method 
of local treatment (e.g., a wound left open to the air forms crusts and eschars different from those 
resulting from the application of wet or greasy dressings), the presence or absence of infection, and 
the surface pressure applied during the burning process. Thus, surface appearance is a product of 
many variables that are related indirectly, if at all, to burn depth. 
sensort responses to noxious stimuli, while thought to be somewhat more reliable than surface appear-ance, 1 15 can also be difficult or impossible to interpret. The main problems here are that the mag-
nitudes of these stimuli are not well controlled in the clinic; individuals vary greatly in their ability 
to give objective responses when under stress, the density of skin innervation is not constant over 
the body surface, and analgesia is often found in deep partial-thickness burns. 
The limitations of standard clinical tests have led to the development of other methods for diagnosing 
the depth of burn inJuries. Perhaps the most widely studied of these methods is evaluation of vascu-
larperfusion and capillary permeability using intravenous tracers. Tracers that have been used 
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include Evans blue,lS 17 Patent blue V,18 19 bromphenol blue,16 fluorescein,2o tetracycline,21 and 
radio-~ctive phosphorous. 8 Major differences among these tracers are (1) specific affinity for blood 
and tissue proteins, which affects the' relative amount of staining due to burn-induced changes in 
capillary permeability, and (2) degree and type of staining reaction produced, which affects the visi-
bility of the tracer below the skin's surface. Not surprisingly then, demarcation of the burn wound 
depends in a complex way on the depth of injury, the thickness of the skin, the tracer used, and 
the time of measurement.' . 
Another method for diagnosing burn injuries is measurement of skin temperatures using thermography 
or thermal probes. This method is based on the expectatio'1 that decreased metabolism and vascular 
perfusion in burned tissue will lower its temperature relative to the surround; indeed, several investi-
gators have demonstrated positive correlations between low temperatures and full-thickness loss. 22-24 
However, thermography currently is not used in many clinics for the purpose of diagnosing burn 
injuries. The main objection to its use is that the temperature patterns measured not only reflect 
metabolism and vascular perfusion, but are functions of skin emissivity, thermal conductivity of the 
underlying tissues, dermal edema, and surface evaporation. 22 25 26 Because none of these latter 
variables are directly related to the depth of burn injury, interpretation of thermograms is subject to 
many sources of error. 
The remaining methods of burn injury diagnosis included in this review are multispectral photographic 
analysis and histological examination of biopsied tissue. A common feature of these methods is that 
their aim is to characterize tissue in the burn wound rather than to measure the flow of blood through 
the region. I n view of the problems associated with interpreting measures of vascular perfusion, this 
approach is logical. The key element in multispectral photographic analysis is comparison of three fil-
tered images of the burn wound. 27 Diagnostic signatures of the biochemical character of the tissues 
are formed by calculating over the entire viewing area the ratios of energies in the red, green, and 
near-infrared portions of the spectrum. The potential artifacts of thermography are avoided to the 
extent that surface temperatures are manifest at wavelengths greater than those of the near-infrared 
band; yet the depth of penetr.ation afforded by the latter is adequate for detection of events in the 
deep dermal layers. In principle then, multispectral photographic analysis integrates information 
present in the surface appearance of the wound along with information present in the spectral reflect-
ance of deeper tissue. In practice, however, one might expect that performance would be degraded 
when the surface appearance is deceptive. Also, multispectral photographic analysis requires a com-
plex array of cameras, optical filters, balanced sources of illumination, a scanning microdensitometer, 
and computer analysis of the images. Widespread clinical use of this method is thus unlikely unless 
improvements in diagnostic accuracy over that of surface appearance alone can be demonstrated, and 
unless these improvements are sufficient to justify the complexity and expense of the procedure. 
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5.2.6 Proposed Ultrasonic Method for Burn Depth Determination 
The proposed ultrasonic method for burn depth determination uses a broadband ultrasonic pulse 
emitted by a clamped high frequency (typically 10-20 MHz) transducer. Such frequencies provide a 
resolution of approximately 0.1 mm in soft tissue. The emitted pulse propagates through a coupling 
path before entering the skin tissue to be characterized. The coupling path also serves as a delay 
line to separate ultrasonic data from high-frequency electromagnetic feedthrough. As the ultrasonic 
pulse propagates through the tissue, echo reflections in the time-domain record are clearly obtained 
from three important anatomical landmarks for partial-thickness burns. The landmarks are (1) the 
interface between the coupling path and the epidermal surface, (2) the interface between the necrotic 
and underlying viable tissue, and (3) the interface between the dermis and the subcutaneous fat. In 
model porcine experiments,28 the time-domain records together with independent in vitro measurements 
of the velocity of sound in porcine skin tissue permitted a quantitative ultrasonic assessment of burn 
depth to within 5 percent of that obtained from histology sections taken from the same burn site. The 
simultaneous display of the three echo reflections provides a real-time indication of relative burn depth 
for partial-thickness burns. 
5.2.7 Clinical Evaluation 
One objective of this Phase 0 study was the selection of a clinical collaborator and the development of 
cofunding for the clinical studies. In this effort, the RTI team interviewed the following individuals. 
Emilie A. Black, M.D. 
Assistant Director for Clinical Research 
National Institute of General Medical Sciences 
National Institutes of Health 
Bethesda, Maryland 
John F. Burke, M.D. 
Professor of Surgery, Harvard Medical School 
Chief of Staff 
Shriners Burn Institute 
Boston, Massachusetts 
Colonel Thomas Camp 
U.S. Army Medical R&D Command 
Ft. Detrick 
Frederick, Maryland 
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Andrew M. Munster, M.D. 
Director 
Baltimore Regional Burn Center 
Baltimore, Maryland 
Basil A. Pruitt, Jr., M.D. FACS 
Colonel, MC 
Commander and Director 
U.S. Army Institute of Surgical Research 
Fort Sam Houston 
San Antonio, Texas 
Project Start 
February 
1983 
1 2 3 4 5 
I. Skin Characterization 
Porcine Skin . ,. 
Human Skin 
II. Instrument Development 
Purchase of Instrument 
Modification of Instrument and Transducers 
Performance Testing 
III. Clinical Testing 
Finalize Test Protocols 
Clinician Training on System (Langley) 
Testing for Diagnostic Accuracy, 
Clinical Utility 
IV. Commercialization 
Identification of Interested Manufacturers 
Selection of Milnufacturer 
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Figure 9. Project Plan for Ultrasound Diagnosis of Burn Depth. 
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As a result of these discussions, Dr. Black has asked NASA to present a paper on the ultrasound 
system at a conference on "New Frontiers in the Understanding of Burn Injuries,lI in Bethesda, Mary-
land, September 26-28, 1983. This confere!,,)ce is sponsored by the National Institutes of Health in 
collaboration with the World Health Organization and the International Society for Burn Injuries. 
All of the clinicians interviewed by the RTI team were enthusiastic about the ultrasound system and 
offered to collaborate with NASA Langley in the project. Dr. Basil Pruitt at the U. S. Army Institute 
of Surgical Research (USAISR) was selected as the primary collaborator on the project. Thermally 
injured patients from both the continental United States and throughout the world are evacuated to 
USAISR. Approximately 225 seriously burned patients are admitted to this facility annually. Major 
objectives of USAISR are (1) the investigation of new diagnostic and therapeutic methods for optimum 
care of the burn patient, and (2) dissem"ination of the scientific advances to military and civilian medi-
cal treatment centers. Approximately 30 research projects are conducted each year at the USA I SR. 
Dr. Pruitt has agreed to collaborate with NASA Langl~y and to conduct the clinical trials at USA ISR 
at no cost to NASA. " " 
5.2.8 Manufacturer Participation 
The RTI team sent an information package on the ultrasound burn depth system to 15 manufacturers 
of medical ultrasound equipment. So far, two companies, Sonometric Systems, Inc., and Technicare 
have expressed an interest in participating in the project and marketing the device. The RTI team 
and Langley researchers visited Sonometric Systems in New York in October 1982 to discuss the proj-
ect. Discussions with manufacturers Will continue, with final selection planned for April 1983. 
5.2.9 Project Plan 
The RTI team worked with the NASA Langley researchers and the other participating organizations to 
develop the project plan shown in Figure 9. 
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6.0 STATUS OF ACTIVE TRANSFER PROJECTS 
CORNEAL TOPOGRAPHY 
BATeam Personnel: Dr. H. Clark Beall 
Problem 
The cornea of the eye is the tough, transparent layer through which light rays must first pass upon 
entering the eye. Trauma and diseases can distort the spherical surface of the cornea to such an 
extent that corneal transplant surgery is required to correct the accumulated refractive error. A new 
surgical procedure, radial keratotomy, is an alternative to corneal transplant surgery. Both proce-
dures require that the surgeon be able to gauge the topography of the corneal surface precisely 
before, during, and after the surgery. 
Solution 
Several optical devices are now available that reflect light from the front surface of the cornea. A 
photographic record can be made of the reflected light pattern; the photo can later be analyzed on an 
optical bench to quantify, in diopter units, the refractive power of a dozen points on the cornea. An 
instrument is desired that can gauge in real time the actual contour, or topography, of the corneal 
surface. . 
NASA Technology 
Two separate items of technology have been proposed by two new research and technology operating 
plans (RTOPs) in response to the RTI problem statement. 
Principals 
Dr. J. Rowsey, surgeon, McGee Eye Institute, Oklahoma City, Oklahoma. 
Mr. Don Griner, Marshall Space Flight Center (MSFC), Huntsville, Alabama. 
Mr. R. Frazer, Jet Propulsion Laboratory (JPL), Pasadena, California. 
Dr. Ralph Helmsen, National Eye Institute, Bethesda, Maryland. 
Cost to NASA 
JPL has received funding from NASA Headquarters for a Phase 0 study, and MSFC has committed 
discretionary funds to support an exploratory study. The device will be evaluated by Dr. Rowsey 
under his current funding from the National Eye Institute. 
Commercialization Strategy 
There appears to be a ready market for a new generation of gauging devices that could be used dur-
ing surgery. Contacts have already been made with several manufacturers who could produce such 
devices. 
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Status 
The prototype device from Marshall will be assembled and tested by an optics contractor. The 
Marshall engineer has prepared the work statement, design specifications, and performance parameters. 
The JPL optical and breadboard are complete. . 
Action 
After the construction and testing of the prototype, Marshall will conduct a demonstration of the 
device. In discussions with the RTI team, Dr. Helmsen has agreed to attend the demonstration. JPL 
will conduct a review of the optics system for NASA headquarters in March before proceeding with 
the computer interface design. . 
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CO,RNEAL TOPOGRAPHY 
- DISTORTED PLACIDO REfLECTIONS fROM 
CORNEASCOPE DIFfiCULT TO ANALYZE 
- NEW SYSTEM NEEDED fOR REAL-TIME 
GAUGING Of CORNEAL TOPOGRAPHY 
- APPROPRIATE NASA TECHNOLOGY: 
OPTICAL GAUGING 
DIGITAL IMAGE PROCESSING 
TV DISPLAY 
-McGEE EYE INSTITUTE/OKLAHOMA CITY 
LOS ALAMOS SCIENTIFIC LABORATORY 
• NATIONAL EYE INSTITUTE 
Corneascope 
50 
CORNEAL TOPOGRAPHY 
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• NEW INSTRUMENT NEEDED fOR REAL·TIME 
GAUGING OF CORNEAL TOPOGRAPHY 
• APPROPRIATE NASA TECHNOLOGY: 
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DIGITAL IMAGE PROCESSING 
TV DISPLAY 
• McGEE EYE INSTITUTE, OKLAHOMA CITY 
LOS ALAMOS SCIENTIFIC LABORATORY 
• NATIONAL EYE INSTITUTE A 
B 
C 
Corneascope photographs of thrt:c .;tages of keratoconus: 
A. early B. progressive C. severe. 
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DIGITAL DATA RECORDER FOR PHYSIOLOGICAL MONITORING 
BATeam Personnel: Dr. H. Clark Beall 
Problem 
There are approximately 20 million insomnia sufferers in the United States. By conservative estimates, 
40 percent of people over 60 years of age have "sleep apnea,lI an inadequate blood oxygen level due 
to a temporary irregularity of respiration. The apnea episodes cause recurrent awakenings during 
sleep at night. The resultant lack of restful sleep causes confusion, drowsiness, irritability, and lack 
of attention during daylight hours. This is especially a problem in the elderly. Researchers who wish 
to study the psychology and physiology of sleep have traditionally brought patients to the laboratory 
where sophistitated instrumentation can record the physiological changes that occur during the various 
sleep stages. They have found, however, that the laboratory environment affects the sleep patterns 
of most patients. What is required is a means of recording physiological data in the home environment 
to reduce costs and improve data quality . 
Principals 
Dr. Elliot D. Weitzman, Montefiore Hospital and Medical Center, Bronx, New York. 
Dr. Fred Hegge, Walter Reed Army Medical R&D Command, Washington, DC. 
Solution 
Most sleep researchers record data on multipen strip chart recorders. ,These recorders are quite 
expensive and not at all portable. Improved sleep monitoring requires a new system of battery-
operated, solid-state, small digital data recorders that can be distributed to patients for use at home 
and returned to the laboratory for readout of the data. 
NASA Technology_ 
NASA TM-812671 describes' a 'digital, solid-state recorder that features a self-contained battery, CMOS 
circuitry, a 2048-worddigital memory, an 8-bit analog-to-digital converter, and an operating capability 
of several weeks. Although the device is used in the NASA Space Shuttle as a temperature recorder, 
the temperature transducer could be replaced with other transducers appropriate for measuring param-
eters 'such as res'piration rate, "movement, muscle activity, eye movement, and body temperature. 
Cost to NAsA 
No C'ostto ,NASA is anticipated fO'r the biomedical application of this device. 
:Commercialization Strategy 
Descriptive literature has been mailed to several prospective manufacturers. 
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Status TM 
The software and hardware that were required for the conversion of an Apple microcomputer into a 
readout station for the digital data recorder units have been completed and are operational at Ames 
Research Center and at the Manned Space Flight Center in Houston. The RTI team has sent a 
description of the recorder and its· possible medical applications to several manufacturers. 
Action 
The new software and hardware must still be documented. One recipient of the RT I package, the 
Industrial Technology Research and Development Foundation of Durant, Oklahoma, has contacts with 
many small businesses in the southwest United States. One of these comp~nies has contacted RT I for 
further information on which to base their marketing decision. 
Reference 
1. Westbrook, R. M., L. D. Bennett, R. A. Steinhauer, and G. J. Deboo. A Solid-State Digital 
Temperature Recorder for Space Use. NASA TM-81267, NASA Ames Research Center, 1981. 
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DIGITAL DATA RECORDER FOR 
PHYSIOLOGICAL MONITORING 
• RECORDING OF PHYSIOLOGICAL PARAMETERS 
DURING SLEEP 
• TEMPERATURE DATA RECORDER DEVELOPED BY 
NASA AMES RESEARCH CENTER FOR SHUTILE 
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• WALTER REED INSTITUTE OF MEDICAL 
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Recorder with cover removed 
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DIGITAL DATA RECORDER FOR 
PHYSIOLOGICAL MONITORING 
• RECORDING OF PHYSIOLOGICAL PARAMETERS 
DURING SLEEP 
• TEMPERATURE DATA RECORDER DEVELOPED BY 
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FLIGHTS 
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• WALTER REED INSTITUTE OF MEDICAL 
RESEARCH 
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HIGH PERFORMANCE WHEELCHAIR 
BATeam Personnel: Dr. Doris Rous~ 
Problem 
Approxfmately 700,000 people in the United States currently rely on wheelchairs for mobility. The 
limitations of available chairs include heaviness, frequent breakdowns, and limited lifetime, resulting 
in high life-cycle cOsts. Recogni?ing these problems, the Veterans Administration (VA) and the 
National Institute of Handicapped Reseqrch have funded several wheelchair research projects. Most of 
these projects are component oriented. Few projects illvolve a full-scale development effort, from 
analysis of requirements through prototype fabrication and evaluation. . 
Solution 
. The use of improved materials as well as computer analysis and simulation could result in an advanced, 
lightweight wheelchair. 
NASA Technology 
. Structure analysis computer programs used in the design of aerospace vehicles would be useful in the 
design of an advanced wheelchair. Graphite composite materials developed for aerospace could be 
incorporated in an advanc~d ch~ir to reduce weight. 
Principals 
.. Mr. Robertaauc;om, MaterjalsApplications Branch, NASA Langley Research Center, Hampton, Virginia. 
Dr. CQlin MCLq~rin, University of Virginia--Rehabilitation Engineering Center, Charlottesville, Virginia. 
Cost to NASA 
.. In 1981, NASA a.lloca.ted $60,000 to this project. An additional $40,000 will be expended by the 
University of Virginia Rehabilitation Engineering Cent!=lr for the design and evaluation of the chair in 
the first year. Funding for the University of Virginia's participation is provided by the. National 
I nstitute of Han<;:iicqpped R~searc;:h. 
Commercialization Strategy 
... Inva'c'qre is v'erY"interested in mprketjng the chair, if the price is reasonable. The RTI team has also 
discl,lssecl participation in this project with severql other wheelchair manufacturers. When a prototype 
is COIllPI et.ed, manufacturers will be invited to Charlot.tesville for a demonstration and discussion of 
commercia.lization. 
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Status 
Fabrication of the initial prototype is going smoothly. The entire upper structure of the chair will be 
made of the Kevlar/foam sandwich material. 
Action 
The initial prototype will be completed in April. The total chair weight is expected to be less than 
25 pounds. The RTI team will work with the University of Virginia in planning a demonstration for 
manufacturers by June. 
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HYDROCEPHALUS SHUNT-~VENTI LATION 
BATeam Personnel: Dr. Dori~ Rouse 
Problem 
Hydrocephalus is a condition in which the cerebral ventricles enlarge abnormally when the pressure of 
the cerebrospinal fluid rises. To relieve this pressure, surgeons implant a shunt to drain the excess 
fluid into other cavities of the body. The shunt frequently fails because the inlet is blocked by an 
ingrowth of choroid plexus or an accumulation of cellular or fibrin debris. 
Solution 
A multi-ended inlet catheter, with hundreds of tiny inlets forll1ed by ion-etching techniques, could 
minimize this problem. The small holes would inhibit tissue ingrowth, and the multiplicity of holes 
would reduce the possibility of blockage. 
NASA Technology 
Technology developed in NASNs Ion Propulsion Engine Program is being used to perforate small-
diameter catheters. 
Principals 
Mr. Bruce A. Banks, Ion Beam Applications Section, NASA Lewis Research Center, Cleveland, Ohio. 
Mr. Eugene Pawlik, Jet Propulsion Laboratory (JPL), Pasadena, California. 
Dr. Eldon Foltz, University of California, Irvine, California. 
Pudenz-Schulte Medical Research Corporation, I rvine, California. 
Cost to NASA 
An RTOP totaling $123,000 was submitted in 1978. First-year funding of $41,000 was approved. An-
other $5,000 was allocated to get the opinions of other medical experts before beginning the second 
year of the project. A $40,000 feasibility study on 2- to 20-micron pores was conducted by JPL in 
1981. NASA has allocated $80,000 to continue this JPL effort in 1982. 
Commercial ization Strategy 
Pudenz-Schulte Medical Research Corporation, a manufacturer of ventricular catheters, was contracted 
by NASA-Lewis to develop an animal model for evaluation of the Lewis prototypes and to conduct bench 
tests for flow studies. Other commercial interests and FDA will be informed of the results on the 
shunt system as they are available. 
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Status 
JPL technical staff has successfully formed 15-micron holes in a Teflon shunt. 
JPL and Don Vargo from NASA Headquarters met with Dr. Terry Hambrecht at 
Neurological Communicative Disease and Stroke to review progress in the prlJject. 
enthusiastiC about the results and suggested several collaborators for clinical tests. 
Action 
Ed Beckenbach from 
National I nstitute of 
Dr. Hambrecht was 
JPL will identify a new clinical collaborator and funding source for evaluation of the shunt. The RT I 
team will assist in identifying neurosurgeons and manlJfacturers if needed. 
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HYPERTHERMIA THERMOGRAPHY 
BATeam Personnel: Dr. H. Clark Beall 
Problem 
The treatment of cancer by localized hyperthermia is a procedure receIving progressively more atten-
tion by oncologists. The generation of hyperthermia at localized sites within the human body can be 
accomplished by ultrasound irradiation, microwave irradiation, or radiofrequency irradiation. The sig-
nificant technical hindrance to the therapy is the requirement for knowledge of the precise temperature 
at the hyperthermia site within the body. Reports in the hyperthermia literature indicate that both 
the exact temperature and the duration of application must be monitored and controlled during hyper-
thermia sessions. 
Solution 
NASA Headquarters assigned Langley Research Center the responsibility of devising a procedure for 
the remote measurement of the temperature within the human body. Initial tests at Langley had shown 
that passive microwave sensing of temperature was not precise enough, or localized enough, to be 
useful during hyperthermia. . 
NASA Technology 
A meeting at the Langley Technology Utilization Office of NASA scientists and an RTI Biomedical 
Applications Team representative resulted in the derivation of several theoretical techniques for meas-
urement of temperature by remote means. The most feasible and most novel method involves the use 
of ultrasound for the detection of phase transitions within strategically located deposits of organic 
crystalline material within or near the hyperthermia site. 
Principals 
Joe Heyman, Ph.D., NASA Langley Research Center, Hampton, Virginia 
Dr. Thomas Cetas, University of Arizona, Tucson, Arizona. 
Cost to NASA 
The approved 1983 RTOP proposed $90,000 total R&D funds for this project. $50,000 has been made 
available to date. 
Commercialization Strategy 
The eventual. result of the effort for hyperthermia thermography is the development of an optimized 
ultrasound scanning system and a set of specially formulated fat compounds with sharply defined melt-
ing points. This custom apparatus should be of commercial value to manufacturers of ultrasound and 
hyperthermia. equipment. 
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Status 
In discussions with the RTI team, Dr. Thomas Strike, the director of hyperthermia at the National 
Cancer Institute (NCI), recommended several clinical hyperthermia researchers who could profit fr,om 
a new precision method of temperature measurement. Dr. Heyman has set up a collaboration with 
Dr. Cetas of the University of Arizona. Dr. Cetas is funded by NC l to evaluate hyperthermia 
techniques. 
Action 
Mr. Bill Swindel, the ultrasound researcher working with Dr. Cetas, will visit Dr. Heyman in April to 
discuss the protocol for animal and clinical trials to be conducted at the University of Arizona. 
Dr. Heyman has been invited to make a presentation on his hyperthermia thermography program in 
Bethesda in May 1983 at the NCI hyperthermia working group meeting. 
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MICROWAVE THERMOGRAPHY 
BATeam Personnel: Dr. H. Clark Beall, 
Problem 
Conventional thermography uses infrared frequencies (>10 GHz) to detect breast cancer. However, 
this technique can only detect thermal profiles at the skin's surface. Subsurface thermal anomalies, 
such as those produced by certain cancerous growths, are indirectly measured as sources of heat that 
affect the thermal profile at the surface. The inability to measure the subsurface thermal profile 
directly is a significant drawback of infrared thermography because: (1) surface and subsurface ele-
ments in the measured thermal profile cannot be differentiated, and (2) thermal dispersion seriously 
degrades the spatial resolution needed to detect heat sources buried beneath the surface. 
Solution 
Microwave thermography can be thought of as a low-frequency analog of infrared thermography. A 
shift to lower frequencies permits detection of thermal profiles up to several centimeters below the 
body's surface. Microwave instrumentation is needed for the high spatial resolution detection of sub-
surface temperature anomalies that are typical of cancerous growth. . 
NASA Technology 
Engineers at Langley Research Center have considerable experience and expertise in microwave re-
search resulting from studies on mi.crowave energy propagation in condensed media. 
Principals 
Mr. Ken Carr, Microwaves Associates, Inc., Burlington, Massachusetts. 
Dr. John D. Buckley, NASA Langley Research Center, Hampton, Virginia. 
Dr. Robert Howell, Medical College of Virginia, Richmond, Virginia. 
Cost to NASA 
The funds committed to this project total $32,500 over 2 years. 
Commercialization Strategy 
A manufacturer of microwave instrumentation is currently participating in the project and plans to 
market the system. 
Status 
The refurbished instrument was found to have 
Medical College of Virginia (MCV) in May 1982. 
factory for repairs. 
Action 
improperly installed batteries upon its arrival at the 
The unit suffered damage and was returned to the 
The MCV evaluation project will be set back 6 months by the equipment problems. The equipment will 
be returned to MeV, in operational order, by April 1983. 
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NONINVASIVE LUNG DIAGNOSIS 
BATeam Personnel: Dr. Doris Rouse 
Problem 
Disabling pulmonary illnesses may develop as a result of occupational and environmental factors, pul-
monary vascular pathology, cystic fibrosis, asthma, or cigarette smoking. Early detection and accurate 
diagnosis of these illnesses give the treatment a greater chance of success. 
Solution 
A technique to record and analyze human respiratory sounds would make possible the detection of vari-
ations in the caliber of the airways and thus the early detection of pulmonary dysfunction. 
NASA Technology 
NASA research in aeroacoustics has provided a basis for a theory of the origin of human respiratory 
sound derived from the motion of vortices in the human lung. This theory has been supported by 
preliminary tests on lung models by the Medical College of Virginia and Langley Research Center. 
Principals 
Dr. Jay C. Hardin, Theoretical Acoustics Branch, NASA Langley Research Center, Hampton, Virginia. 
Dr. John L. Patterson, Jr., Medical College of Virginia, Richmond, Virginia. 
Mr. John E. Wootten, B&K Instruments, Inc., Cleveland, Ohio. 
Cost to NASA 
Approximately $61,000 in FY80 and FY81 funds were approved for this project. An FY83 RTOP ·for 
$40,000 was submitted. The Medical College of Virginia has allocated $15,000 from the Hundley Fund 
to support this work. In addition, an NIH Research Career Award supports Dr. Patterson1s time on 
the project at a cost of approximately $30, OOO/year over a 5-year period. Recently, Dr. Patterson 
was awarded a Jeffr~ss Research Grant for- $79,000 for this project. B&K Instruments, Inc., has 
already contributed Mr. Wootten1s consulting time during several trips to the Medical College of 
Virginia. In a February 4, 1983, letter to John Samos, TUO, Langley Research Center, B&K Instru-
ment, I nco I described their plans to support this project with engineering consultation and equipment. 
Commercial ization Stretegy 
B&K Instruments, Inc., has written to John Samos, TUO, Langley Research Center, indicating their 
interest in this diagnostic system as a commercial product. They predict a market for the system in 
employee industrial checkup centers as well as in hospitals. B&K and the Medical College of Virginia 
will continue to collaborate on this project. 
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Status 
Clinical testing of the model awaits completion of the semi-anechoic chamber at the Medical College of 
Virginia. An RTOP for continued NASA support of this project was submitted by Langley Research 
Center. The RTI team obtained very positive reviews of the project from two pulmonary researchers 
and clinicians. 
Results of this work have been published in the following: 
Hardin, Jay C., and John L. Patterson, Jr. Taking Soundings of the Lungs. Airways, 4(1), 1979. 
Hardin, Jay C. Noise Calculation on the Basis of Vortex Flow Models. NASA Tech Brief LAR-12271, 
Spring 1978. . 
Hardin, Jay C., and John L. Patterson, Jr. Theory of Sound Generation in the Human Lung. Pre-
sented at the Mid-Atlantic Conference on Bio-Fluid Mechanics, Blacksburg, Virginia, August 10-12, 
1978. . 
Hardin, Jay C., and John L. Patterson, Jr. Monitoring the State of the Human Airways by Analysis 
of Respiratory Sound. ACTA Astronautica, 6(9), September 1979. 
Hardin, Jay C., and John L. Patterson, Jr. The Pressure Flow Realation in Bronchial Airways on 
Expiration. Presented at the Mid-Atlantic Conference on Bio-Fluid Mechanics, Blacksburg, Virginia, 
May 5-7, 1980. 
Hardin, Jay C., and John L. Patterson, Jr. Genesis of Breath Sounds: Theory and Application. 
Presented at the Fifth I nternational Conference on Lung Sounds, London, England, September 15-16, 
1980. 
Hardin, Jay C., and John L. Patterson, Jr. Genesis of Breath Sounds: Theory and Application. 
Presented at the Federation of American Societies for Experimental Biology, 65th Annual Meeting, 
Atlanta, Georgia, April 12-17, 1981. 
Action 
In the next quarter, the RTI team will work with Dr. Patterson to document the project plan in more 
detail. 
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NONINVASIVE LUNG DIAGNOSIS 
• DETECTS PULMONARY DYSFUNCTION BY 
ANALYZING FREQUENCY AND AMPLITUDE OF 
LUNG SOUNDS 
• RESPONSE TO PHARMACOLOGICAL AND 
ENVIRONMENTAL STIMULI 
• NASA LANGLEY ACOUSTICS TECHNOLOGY 
• MEDICAL COLLEGE OF VIRGINIA, RICHMOND 
B & K INSTRUMENTS, INC., CLEVELAND, OH 
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PORTABLE COOLING SYSTEM FOR QUADRIPLEGICS 
BATeam Personnel: Dr. Doris Rouse 
Problem 
Quadriplegics are vulnerable to heat stress because they cannot perspire below the level of injury, a 
condition that results from the interruption of autonomic neural pathways that mediate thermoregula-
tory perspiration and vasomotion. Quadriplegics exposed to even moderately high temperatures risk 
hyperventilation, increased heart rate, and heat stroke. 
Solution 
A portable cooling garment would eliminate these risks, thus opening new employment and daily living 
opportu'lities for individuals previously confined to temperature-controlled environments. 
NASA Technology 
Technology from the development of thermal control garments to protect astronauts has been used to 
make a water-cooled vest for quadriplegics. 
Principals 
Ms. Pat Kirk, Environmental Control Research Branch, NASA Ames Research Center, Moffett Field, 
California. 
Dr. Inder Perkash, Spinal Cord Injury Unit, Veterans Administration Medical Center, Palo Alto, 
California. 
Cost to NASA 
Fabrication of prototype vest systems for evaluation by VA Palo Alto cost NASA $15,000. The in-kind 
cost to the VA Palo Alto for the evaluation at VA Palo Alto will be approximately $15,000. 
Commercialization Strategy 
Palm Beach Medical Corporation, who has expressed an interest in marketing the quadriplegic cooling 
vest, is .following the evaluation. Other manufacturers will be contacted as well. 
Status 
Personnel at Ames Research Center designed a small water-cooling and pumping unit for use with the 
vest. An informal evaluation of the system by a quadriplegic indicated that the system was quite 
effective. The VA Medical Center in Palo Alto has prepared a protocol for evaluation of the vest in 
the NASA Ames environmental chambers and in outpatient use. 
Action 
The evaluation by the Veterans Administration will begin in April 1983. 
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PORTABLE COOLING SYSTEM FOR QUADRIPLEGICS 
• QUADRIPLEGICS UNABLE TO PERSPIRE 
BELOW LEVEL OF INJURY. VULNERABLE TO 
HEAT STRESS 
• NASA THERMAL CONTROL TECHNOLOGY 
• COOLING VEST AND PUMPING/CHILLING 
UNIT 
• SPINAL CORD INJURY UNIT, VA MEDICAL 
CENTER, PALO ALTO, CA 
VA REHABILITATION RESEARCH AND 
DEVELOPMENT, WASHINGTON, DC 
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Portable cooling system. A = reservoir, B = battery, 
C = pump. 
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PROGRAMMABLE IMPLANTABLE MEDICATION SYSTEM 
BATeam Personnel: Dr. Doris Rouse 
Problem 
A number of chronic diseases require long-term infusion or frequent injections of medication. An im-
planted pump has been used for the continuous, intravenous infusion of heparin in patients for more 
than 24 months. One million diabetics in the United States depend on daily insulin injections to help 
control blood sugar levels; one in ten of these is a child. 1 A programmable implantable pump capable 
of several delivery rates would be extremely useful in the infusion of insulin to treat diabetes. A more 
reliable control of blood sugar levels throughout a diabetic's life is thought to diminish the incidence 
of the complications associated with diabetes--kidney disease, diabetic retinopathy, atherosclerosis, 
and heart attacks. 2 3 4 
The conventional treatment for controlling blood sugar levels in the diabetic requires two to four insu-
lin injections daily. In addition, the patient must accept significant lifestyle and diet restrictions. 
Despite these efforts, however, true normalization of blood glucose is rare, because of changes in daily 
activity levels, changes in diet, and shortcomings in the insulin delivery system. 
Plasma glucose concentration in healthy subjects remains between 70 and 120 mg/dL over a 24-hour 
period. 4 In contrast, a patient with juvenile-onset diabetes, who is taking multiple, daily insulin 
injections, will still have a hyperglycemic plasma glucose concentration of more than 200 mg/dL. The 
diabetic may also experience periodic hypoglycemia (plasma glucose less than 50 mg/dL). 5 Tamborlane 
et al. recently reported that good plasma glucose control could be obtained in juvenile diabetes patients 
by the use of a portable insulin infusion system that delivers a basal rate of insulin with a prepran-
dial pulse. 6 An implantable infusion system that could achieve the plasma glucose control demonstrated 
in this external system would have obvious advantages. 
Solution 
An implantable infusion pump that could accurately deliver medication at programmed rates would have 
great potential in the treatment of several diseases including diabetes, leukemia, thalassemia, and 
hormone disorders. Safety features and reliable delivery rates would be required to insure safe medi-
cation levels. 
NASA Technology 
The programmable implantable medication system (PIMS) will incorporate NASA technology in three 
areas: (1) microminiaturized hybrid circuitry will be used for the pump system as well as the pro-
gramming unit, (2) the programming unit will use command and telemetry systems with functions sim-
ilar to those used on small astronomy satellites and other spacecraft, and (3) aerospace technology in 
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miniature, highly reliable hydraulic control systems will be used in the medication delivery portion of 
the system. 
Principals 
Mr. Don Friedman, Technology Utilization Officer, Goddard Space Flight Center. 
Mr. Robert Fischell, Applied Physics Laboratory, Johns Hopkins University, Laurel, Maryland. 
Mr. AI Mann, P~cesetter Systems, Inc., Sylmar, California. 
Mr. Steve Wirtz, Parker-Hannifin/Biomedical Products Division, I rvine, California. 
Dr. Christopher Saudek, Johns Hopkins University, Baltimore, Maryland. 
Cost to NASA 
An FY80 RTOP from Goddard Space Flight Center was approved for $150,000, with $950,000 in pro-
jected costs for the next 3 years. A Marshall Space Flight Center FY80 RTOP was approved for 
$75,000, with projected costs of $135,000 over the following 2 years. In March 1980, management of 
the hydraulic control RTOP was transferred to Goddard Space Flight Center. The cost sharing for 
the project is listed below: 
National Institute of Child Health and Human Development (NICHHD) 
Wilson-GreatbaGh Limited 
National Institute of Arthritis, Diabetes, and Digestive and 
Kidney Diseases (NIADDKD) 
Pacesetter Systems, Inc. 
Parker-Hannifin, Inc. 
Applied Physics Lab (APL) 
Baker Foundation 
Total cost sharing 
Commercialization Strategy 
Pacesetter Systems and Parker-Hannifin plan to manufacture and market the PIMS. 
Status 
$ 400,000 
500,000 
2,500,000 
2,000,000 
3,000,000 
50,000 
2,500 
$~452~oa 
The second phase of the animal trials, long-term implants, has begun at Johns Hopkins. Two PIMS 
units are currently operating in diabetic dogs in Dr. Saudek's laboratory. The push-cart Medication 
I njection Unit originally designed for PIMS has been replaced by a hand-held syringe system. The 
NICHHD committed $400,000 to the evaluation of PIMS for reproductive endocrinology. Extensive 
testing of the peptide hormones by NICHHD has shown sufficient stability for use in PIMS. The RTI 
team discussed the use of PIMS for hepatic artery infusion of chemotherapy with Dr. Paul Sugarbush, 
a colorectal surgeon at the National Cancer Institute. NCI is currently conducting a trial for hepatic 
infusion using the Infusaid pump and is interested in using the same protocol with the PIMS. The 
RTf team participated in the PIMS working group meeting at APL November 10, 1982. 
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Action 
Dr. Saudek will continue the long-term animal studies. With continued good results, human implants 
are expected in 1983. The RTI team will work with Don Friedman and APL to identify program 
directors at the National Cancer Institute who may be interested in supporting an evaluation of PIMS 
for intraspinal infusion of morphine for pain relief in terminal cancer patients. 
References 
1. Schapiro, George A. Medical Electronics, p. 55, June 1979. 
2. Cahill, G. F., Jr., D. D. Etzweiler, and N. Freinkel. New England Journal of Medicine, 
294: 1004, 1976.-
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PROSTHETIC URINARY SPHINCTER 
BATeam Personnel: Dr. Doris Rouse 
Problem 
A malfunctioning urethral sphincter is often responsible for the inability to control emptying of the 
bladder. This condition may result from congenital, traumatic, postsurgical, or neurogenic disorders. 
Continence can sometimes be restored by an implanted device that occludes the urethra and allows vol-
untary voiding by manual rel,ease of the occluding pressure. Two factors currently prevent widespread 
acceptance of such devices by the medical community: (1) the surgical complexity of the implantation 
procedure and (2) a high rate of device malfunction, often the result of valve failure. 
Solution 
A simpler, more reliable system is needed for occluding the urethra. 
NASA Technology 
The low-pressure, "zero" leakage, high-reliability valves used in the Viking project have been adapted 
for use in a prosthetic urinary sphincter. . 
Principals , 
Mr. John B. Tenney, Department of Surgery, Rochester General Hospital, Rochester, New York. 
Mr. Steven Wirtz, Parker-Hannifin Corporation, I rvine, California. 
Mr. Dave Sanders, President, Medical Engineering Corporation, Racine, Wisconsin. 
Cost to NASA 
NASA's total cost was $203,000. Parker-Hannifin Corporation has invested $250,000. Medical Engi-
neering Corporation (MEC) has invested $250,000. In-kind contributions by Rochester General Hospital 
(RGH) have totaled.$25,000. 
Commercialization Strategy 
MEC will market and distribute the system worldwide. Parker-Hannifin will supply the hydraulic con-
trol portion of the system. MEC and Parker-Hannifin are currently developing two other medical 
devices that utilize the NASA valve developed by Parker-Hannifin, a penile prosthesis and a continent 
colostomy device. 
Status 
RTI arranged a meeting between Parker-Hannifin, MEC, and Dr. Paul Sugarbush, a colorectal surgeon 
at the National Cancer Institute, to discuss NCI evaluation of the colostomy cuff. 
Action 
MEC plans to begin human implants of the urinary sphincter by September 1983. The RTI team is 
discussing possible funding for this evaluation with Paralyzed Veterans of America. 
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NASA press/relieve valve concept of 
prosthetic urinary sphincter 
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TEXTURING FOR PERCUTANEOUS CONNECTORS 
BATeam Personnel: Dr. Doris Rouse 
Problem 
Percutaneous connectors are conduits through the skin that facilitate the transmission of fluids or 
connecting devices between the external environment and the body's internal milieu. Current percu-
taneous connectors are unacceptable for long-term implants because of externalization and infection. 
Solution 
If percutaneous connectors could be developed with a reduced tendency to externalize and with an 
improved body fluid ~eal to inhibit bacterial invasion, morbidity could be greatly reduced and new 
device applications could be explored. 
NASA Technology 
NASA electron propulsion technology may be used to ion-beam texture percutaneous connectors to 
prevent externalization and reduce infection. 
Principals 
Mr. Sandy Felder, NASA Lewis Research Center, Cleveland, Ohio. 
Dr. George Picha, President, Applied Medical Technology, Inc., Lakewood, Ohio. 
Cost to NASA 
An FY80 RTOP was submitted for $155,000 over a 3-year period. Cost sharing by the potential manu-
facturer will be $252,000 over 4 years. 
Commercialization Strategy 
A NASA patent disclosure has been filed. Applied Medical Technology, Inc., plans to market textured 
connectors if the study proves successful. American Hospital Supply (AHS) Corporation is interested 
in collaborating with Applied Medical Technology to commercialize several devices using NASA's ion-
texturing. 
Status 
The RTI team discussed this project with Drs. Watson and Berson in the Devices and Technology 
Branch, National Heart, Lung and Blood Institute (NHLBI). They found that the technical objectives 
of the NASA project were satisfactory and that the preliminary results were promising enough to 
warrant continued project support. NHLB I is supporting two contractors to develop percutaneous 
connectors. The RT I team has forwarded recent reports by the contractors to Dr. Picha. The RT I 
team attended an NHLBI contractors meeting in Bethesda. Work thus far has demonstrated that a 
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regular array of micropillars can inhibit epithelial downgrowth and subsequent rejection of the per-
cutaneous connector. AHS would like to participate in and cofund the remaining 2 years of develop-
ment for the percutaneous connectors. Pending patent protection negotiations, AHS would conduct 
and finance the clinical trials. Implementation of this plan for collaboration is under consideration by 
NASA Lewis, NASA Headquarters, and AHS. 
Action 
Discussions will continue with AHS on cofunding and requirements for patent protection. 
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PERCUTANEOUS CONNECTORS 
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Scanning electron micrograph of ion-beam textured surface 
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TEXTLI~H'>lG SURFACES FOR CARDIOVASCULAR PROSTHESES 
BATeam Personnel: Dr. Doris Rouse 
II i. 
Problem 
The. ideal vascular prosthesis should promote the formation of a stable, nonthrombogenic blood inter-
f 9ce. A material with this property would be useful for heart replacements, as heart-assist devices, 
and in vascular applications. 
Solution 
Stu~:Hes have shown that a surface with a microstructure will produce a thin, uniform, and well-
nourished neo-intima, or layer of blood components and cells. A thin neo-intima is desirable because 
it is less thrombogenic. The thickness of the neo-intima that develops on a heart-assist device bladder 
is directly related to the height of the pillars text4ring the surface. Present mold-manufacturing tech-
nology limits this pillar height to a minimum of 250 J.lm. A technique to produce shorter pillars on 
the material may produce ~ thinner, less thrombogenic neo-intima. 
NASA Technology 
NASA electron propulsion technology can be used to make materials with smaller pillar heights. 
Principals 
Mr. Bruce Banks, NASA Lewis Research Center, Cleve/and, Ohio. 
Thermo Electron Corporation (TECO), Waltham, Massachusetts. 
NCltional Heart, Lung and Blood Institute. (NHLBI), Bethesda, Maryland. 
Cost to NASA 
An FY80 RTOP for $133,000 over 3 years was funqed. Cost sharing by NHLBI and TECO will be 
$119,000. 
Commercialization Strategy 
Successful ion-beam texturing would improve the vascular prostheses currently on the market as well 
as heart-assist devices, when they are available. Manufacturers of vascular prostheses will be pre-
sented with the results of this work on heart-assist pUfTlP bladders. 
Status 
Nt-iLBI has cofunded a joint effort between TECO and NASA Lewis Research Center to fabricate six 
ion-textured bladders for left ventricular assist devices. This work complements an NHLBI-funded 
project at the University of Utah entitled "Development and Evaluation of Textured Surfaces. II Under 
a contract from NASA Lewis Research Center, Diecast Dies, Inc., textured the mandrils and formed 
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bladders. The bladders were delivered to the University of Utah and TECO researchers for implanta-
tion and evaluation in calves. 
Action 
The implanted bladders will be retrieved this year for examination of the neo-intima formed on the 
textured surface. The RTI team will continue discussions with NHLBI on project results and plans. 
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Artificial heart assist pump 
Scanning electron micrographs of carbon-impregnated polyolefin 
before and after sputter etching. 
ULTRASOUND DIAGNOSIS OF BURN DEPTH 
BATeam Personnel: Dr. Doris Rouse ~~~~~~~~' -
Problem 
Approximately 2 million Americans suffer serious burns each year, and 200 to 300 thousand of these 
people require hospital treatment. 1 Among those hospitalized, 70,000 receive intensive care and 10 to 
12 thousand patients die from their injuries. The cost of intensive care exceeds $300 million per 
year.2 The traditional treatment of burn victims is to allow natural debridement, sloughing of necrotic 
tissue, to occur and then to close the resulting open wounds with skin grafts. Unfortunately, the 
weeks required for spontaneous sloughing often result in infection and sepsis; indeed, the major cause 
of death in burn victims is bacteri~1 infection. 3 Modern treatment, therefore, is based ()n early recog-
nition and removal of necrotic tissue to reduce infection and hasten healing. This surgical or chemical 
debridement depends upon accurate burn depth information for optimal results. Current methods for 
burn ~epth determination are inaccurate, cumbersome, or both. 
Solution 
Ultrasound may be used to map precisely and conveniently the depths of the interface between viable 
and necrotic tissue in burn injuries. Preliminary studies in pigs demonstrate a good correlation 
between depths of burn measured by pulse-echQ ultrasound and by histological techniques. 
NASA Technology 
Advanced ultrasonic technology developed at Langley Research Center for the characterization of 
materials is directly applicable to this project. 
Principals 
Dr. John H. Cantrell, Jr., Langley Research Center, Hampton, Virginia. 
Dr. Tom Yost, Langley Research Center, Hampton, Virginia. 
Col. Basil Pruitt, Jr., M.D., U.S. Army Institute of Surgical Research (USAISR), Ft. Sam Houston, 
Texas. 
Cost to NASA 
Estimated cost for development of the prototype is $146,000. Estimated cost to the Army for evaluation 
of the device is $210,000 in the first year. 
Commercialization Status 
The RTI team has contacted 15 manufacturers of medical ultrasound devices. Thus far, Technicare 
and Sonometrics Systems, Inc., are interested in collaborating in the project and marketing the 
device. The RTI team and the Langley - scientists visited Sonometrics in October to discuss the 
system. 
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Status 
An FY83 RTOP for $126,000 has been submitted by Langley Research Center for support of the 
project. In response to inquiries by the RTI team, four major burn centers, Shriners Burn Center-
Harvard, Medical College of Virginia, the Baltimore Regional Burn Center, and the USAISR at Ft. Sam 
Houston, have indicated a strong interest ~n conducting the clinical evaluation of the system. The 
USAISR has agreed to evaluate the device at no cost to NASA. 
Action 
The RTI team and Langley scientists will visit USAISR to discuss the system and the clinical protocols 
for evaluation. Selection of the manufacturer will be completed by May 1983. Dr. Cantrell has been 
invited to present a paper on the device at a conference on b\Jrns in September 1983. This conference 
will be sponsored by the National I nstitutes of Health, World Health OrgCinization, and the International 
Society for Burn Injuries. 
References 
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WASTEWATER TREATMENT BY VASCULAR AQUATIC PLANTS 
BATeam Personnel: Dr. H. Clark Beall 
Problem 
The purification of wastewater is a problem faced by municipal treatment plants throughout the United 
States. The effluent from such pl~nts must meet standards set by EPA before it can be released from 
the treatment plant. Sanitation engineers are searching continually for new technologies that can be 
applied to water treatment to reduce costs, time, and energy required to process wastewater. 
Solution 
Use of aquatic plants, one of several new procedures for wastewater treatment, shows promise in terms 
of speed, operating ~ost, and effectiveness .. 
NASA Technology 
Research at the National Space Technology Laboratories has focused on the treatment Qf wastewater 
by vascular aquatic plants. The first effort dealt with a system based on the water hyacinth, Eich-
hornia crassipes. This system worked well in warm climates in wastewater treatment and biomass 
energy production. 
Principals 
Bill Wolverton, Ph.D., National Space Technology Laboratories, Mississippi. 
Cost to NASA 
The current RTOP request for this work is $40,000 with an additional $80,000 being funded by EPA. 
Commercialization Strategy 
The City of San Diego is now using the water hyacinth system as one means to bring ~ffluent water 
to potable standards. An engineering firm from Baton Rouge, Louisiana, Owens and White, Inc., has 
based its designs for two new municipal treatment plants on the NASA-published data of microorganism/ 
vascular plant wastewater treatment. The designs are being reviewed by EPA and await local funding 
under the Innovative Technology program of the State of Louisiana. 
Status 
There are thousands of small food-processing plants in the United States that could benefit from treat-
ment of wastewater by vascular plant systems. Dr. Wolverton has agreed to assist in the design of a 
wastewater treatment plant for a crab meat processin$} plant in Crestfield, Maryland. 
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Action 
The RTI team will work with faculty members of North Carolina State University Food Science Depart-
ment, Raleigh, North Carolina, to evaluate applications in the food processing industry, especially 
poultry processing plants. 
Reference 
Wolverton, B. C. New Hybrid Wastewater Treatment System Using Anaerobic Microorganisms and Reed 
(Phragmites communis). NASA Technical Memorandum, TM-X-72739, June 1981. 
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7.0 INACTIVATED PROJECTS 
COMPOSITE MATERIAL APPLICATIONS 
BATeam Personnel: Dr. Doris Rouse 
This project has been integrated into the high performance wheelchair proj~ct. In that project, com-
posite'materi~ls are being used to decrease the weight of a stand~rd wheelchair from 50 to 25 pound~. 
DETECTION OF A DISLODGED TEMPERATURE PROBE 
BATeam Personnel: Dr. H. Clark Beall 
I nfant radiant warmers ,!re widely used in hospital delivery rooms and nurseries to maintain the correct 
body temperature of newborn babies. These devices, which radiate energy in the far infrared spec-
trum, are servocontrolled via a patient temperature probe that attaches to the infantls skin. If the 
probe becom~s dislodged, the warmer may deliver excess radiation' to the infant. In discussions with 
the RTI team, the Association for the Advancement of Medical Instrumentation indicated that a sensor 
was needed to alert the staff if the temperature probe were dislodged. Lewis Research Center sub-
mitted a sensor design in response to an RTI team problem statement. The' RTI team distributed the 
. concept to radiant warmer' manufacturers. One letter of reply advised RTI that the same technology 
was currently under development as a proprietary device. 
FIBER OPTICS SYSTEM FOR KNEE SURGERY 
BATeam Personnel: Dr. H. Clark Beall 
A second test of the utility of the fiber optics system as an orthoscope-TV camera interface took place 
in 1982 at Duke University Medical Center. Light passed by the fiberoptiCs system was insufficient to 
produce an acceptable color TV image. Both t~sts of the fiber optics system indicated its limitations 
as an adequate surgical imaging device. In addition, there are now on the market s~veral very small, 
low-light, color TV cameras specifically designed for medical applications. These color TV cameras 
will fill the need for which the fiber optics device was originally developed. The fiber optics device 
has been returned to Langley Research Center, accompanied by a memorand!Jm describing the clinical 
eval uations. 
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LOW-COST UV OPTICAL DOSIMETER 
BATeam Personnel: Dr. H. Clark Beall 
Engineers at Langley Research Center demonstrated how the technologies of the photovoltaic solar cell 
and the electrochemical current-recording cell could contribute to the extremely simple design of a 
solar dosimeter to detect and integrate the incident solar irradiation over long periods of time. 
Several models of the solar dosimeter were fabricated. The entire instrument was so small that it 
coulg be worn unobtrusively or attach~d to eyeglass frames. 
An effort was mage to construct dosimeters that recorded exclusively the UVB radiation from the sun. 
The UVB radiation is the portion of solar radiation that causes sunburn, initiates suntanning, and 
perhaps causes skin cancer in humans. Although prototypes of the UVB dosimeters se~med to operate 
satisfactorily in laboratory tests, efforts to produce a batch of more than a dozen identical units 
produced instead a set of devices having a diversi'ty of spectral responses. Special optical filters are 
required to isolate the UVB band from the total solar radiation adequately. I n addition, special blue-
sensi,tive detectors are required to convert the UVB radiation to electric current. The cost of these 
special items exceeded the cost of the basic dosimeter by twenty-fold, thus compromising the low-cost 
feature of ,the ,original dosimeter design . 
. P9.RTABLE X-RAY FLUORESCENCE SPECTROMETER 
BATeam Personnel : Dr. H. Clark Beall 
The concept of using the X"r~y fluorescence technique outside the laboratory has been proved by a 
LangteyR,esearch ,Center researcher, Warren Kelliher, Ph. D. He has designed ang contract.ed the 
fabric~tion of a hand-helg, portable X-ray fluorometer. The device has been evaluated in several 
applications projects. The first project was jointly funded by NASA and the U.S. Bureau of Mines to 
test ,the X-ray flqorometer in the onsite elemental analysis of ores and prospect samples. The second 
project ge~onstr.ated the use of the device as a quantitative detector of heavy metals in water samples 
for the EPA laboratory in Las Vegas. The device has also been used to type the exact metal alloy of 
aircraft parts without dismounting or damaging the parts. The gevice can similarly be used to quickly 
verifyi,ndividual alloys of metal stock in aircraft an,d shipbuilding facilities and at machine shops. 
The X-raY fll,JorQmeter .has .b.een improved in the last several years by the addition of new detector 
crystals .and detector head configuration. A patent disclosure' of the device has been prepared 
<;iescribing the device's configuration during the Bureau of Mines project. 
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The RTI team interviewed clinicians to identify potential medical applications for the X-ray fluorometer. 
Staff members of the Department of Radiology of the Duke University Medical School considered' their 
requirements for a portable X-ray fluorometer and found that their needs were adequately served by 
mobile X-ray fluorometer units that utilize AC power sources. 
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8.0 CONCLUSIONS 
During the reporting period, the RTI Biomedical Applications Team conducted problem-solving and commer-
cialization activities for 15 active projects, 2 commercial transfers ( and 2 institutional transfers. Each of 
these projects lias the potential for introducing new or improved commercial medical devices incorporating 
~ASA technology. The proje~ts s~lected by the team reflect an emphasis on transferring NASA technology 
via the introduction of commercially availabl~ devices. The objective of this commercial emphasis is' to 
achieve widespread availability of the devices developed in the technology transf~r process. To accomplish 
this commercialization objective, the RTI team has continued to develop improved methods for project selec-
tion and development. l!Tlplementation of techniques developed by the RTI team for reducing the time and 
costs for transfer of the technology has resulted in a more effective utilization of the funds available to 
the team, NASA field centers, and participating agencies. Techniques implemented during the reporting 
period to enhance the team's efficiency are described below. . 
1. Washington Office 
Close collaboration between the RTI team and Federal health agen~ies in the identification 
and screening of opportunities and the selection of clinical investigators has been effective 
in establishing successful technology transfer projects that address significant requirements 
in medicine. Most of the agencies that participate in the NASA program are located in the 
Washington, DC, area: The National I nstitutes of Health, National I nstitute of Handicapped 
Research, Veterans Administration, and Paralyzed Veterans of America. In the past year, 
Mr. Bernard Maggin and Mr. William Penland, Jr., have served as consultants for the RTI 
team in the Washington, DC, area. They' have assisted the team in developing and imple-
menting strategies for collaboration with Federal agencies in NASA applications projects. 
The objectives of the RTI team in establishing this Washington office were: (1) to est~blish 
more effective communication with the agencies, and (2) to decrease the team's travel costs 
associated with agency collaboration. I n this first year of operation, the Washington office 
has proven to be quite an effective and efficient method for expanding the team's access to 
other agencies. 
2. Phase 0 Studies 
At the request of NASA Langley Research Center and NASA Headquarters, the team has 
conducted two Phase 0 studies in the past year. The objectives of these studies were to 
evaluate the technical feasibility of the project; evaluate the market and the' economic feasi-
bility of the concept, establish mission agency collaboration and cofunding, identify a clinical 
investigator, and establish manufacturer interest in the project. These Phase 0 studies have 
provided a basis for the development of a more effective project plan. 
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Data gathered in the study and discussions with collaborating organizations identified in the study 
clarify the objectives of the project. As a result, the development project following the Phase 0 study 
~ill be more directed and thus more cost effective. . 
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APPENDIX A. TRAVEL 
January 25, 1982 
February 4, 1982 
~ 
February 5, 1982 
February 23, 1982 
February 24, 1982 
February 25-26, 1982 
March 25-27, 1982 
May 24, 1982 
April 6, 1982 
April 9, 1982 
April 22, 1982 
April 23, 1982 
Dr. J. N. Brown, Jr., met with RClY Whitten at NASA Headquarters to discuss RTI 
team projects. 
Dr. Doris Rouse participated in the planning session for the High Performance 
Wheelc!1air project at Langley Research Center. 
Dr. Doris Rouse visited the University of Virginia to continue discussions on the 
high performance wheelchair and the NASA Lewis-UVa wheelchair battery project. 
Dr. Doris Rouse met with Dr. John L. Patterson to discuss the status of the Non-
invasive Lung Diagnostic Device at the Medical College of Virginia. 
Dr. Doris Rouse met with Mr. John Samos, Mr. Les Rose, and Mr. Ray Whitten at 
Langley Research Center to discuss several projects. 
Dr. Doris Rouse participated jn the Programmable Implantable Medication System 
working group meeting at Applied Physics Laboratory, Laurel, Maryland. 
Dr. Doris RoLlse participated in the Wheelchair III Conference at La Jolla, California. 
Th~ Veterans Administration Rehabilitation Engineering Research and Development 
Service sponsored this· conference and funded Dr. Rouse's travel. 
Dr. Clark Beall attended a presentation for EPA representatives at Langley Research 
Center on the capabilities of the NASA quadrupole mass spectrometer system. 
Dr. Doris· Rouse met in Washington with Dr. Giannini, Director, Rehabilitative Engi-
neerihg Research and Development for the Veterans Administration to discuss 
NASA/VA collaboration on rehabi litation projects. 
Dr. James Brown met with Technology Utilization Office representatives at Kennedy 
Space Cehter to discuss plans for FY83 RTOPs. . 
Dr. DOris Rouse met with Dr. Jim Beebe and Don Vargo at the Science and Tech-
nology I nformation Facility, BaltilTlore, to discuss technology summaries for NIH. 
Dr. Doris Rouse met with Don Friedman, Goddard Technology Utilization Officer, 
to discuss the CSF control system Phase Zero study. 
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April 23, 1982 
May 5, 1982 
May 11, 1982 
May 12, 1982 
May 24, 1982 
May 261. 1982 
June 3, 1982 
June 9, 1982 
June 23-24, 1982 
June 28-30, 1982 
July 29-30, 19~2 
August 12, 1982 
Dr. Doris Rouse met with Lynn Phillips, Director of Research, Paralyzed Veterans 
of America, in Bethesda to discuss wheelchair innovations. . . 
Dr. Doris Rouse met with the marketing and engineering staff at C~ ... dis Corp., 
Miami, to qiscuss the C~F control system project. 
Or. James Brown and Dr. Doris Rouse met at NASA Headquart~rs with Ray Whitten, 
Don Vargp, and Don Friedman to discuss status of Biomedical Applications Team 
projects. 
Dr. Doris Rouse participated in a meeting in Washington, sponsored by the Veterans 
Administration, to identify new technology and designs for power wheelchairs. 
Blake Wi Ison and Dr. Doris Rouse met with John Samos, Les Rose and Dr. John 
Cantrell, Jr., at Langley Research Center to discuss the Ultrasound Diagnosis of 
Burn Depth. . 
Dr. Doris Rouse met· with Dr. George Picha, Sandy Felder:, ~nd Roger Drake, 
Director of the American Hospital Supply Technology Center, to discuss commercial-
ization of ion-textured devices developed by NASA. 
Dr. James Brown and Dr. Doris Rquse met at NASA Headquarters with Charles Yost 
to discuss a proposed shuttle experiment on blood preservation. 
Dr. James Brown and Dr. Doris Rouse coordinated a meeting at the Pentagon with 
Col. Phillip Winter, M. D., and Parker-Hannifin representatives to discuss the 
NASA TU program and military medical applications of the MICROMED. 
Dr. Doris Rouse participated in the 9th PIMS Working Group Meeting at Applied 
Physics Laboratory, Laurel, MD. . 
Dr. Doris Rouse participated in the Advisory Design Committee Meetl~g for the 
Association for Retarded Cjtizens in Arlington, Texas. 
Dr. Doris Rouse m~t with John Samos, Les Rose, and Don Vargo at Langley 
Research Center to discuss Langley Technology Utilizatiol') projects. 
Bill Penland, Bernie Maggin, and Dr. Doris Rouse met with Don Vargo at NASA 
Headquarters to prepare for the RTOP review. 
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August 17, 1982 
August 20-26, 1982 
August 24, 1982 
August 26-27, 1982 
August 31, 1982', 
September 1-2, 1982' 
September 15, 1982 
October 7, 1982 
October 8, 1982 
October 13'11 1982 
October 14:" 1982 
Dr. Doris Rouse participated in a Washington meeting sponsored by the Veterans 
Administration Rehabilitation Research and Development to prepare specifications 
for a power wheelchair Request for Proposal. 
Dr. Doris' Rouse participated in the conference of the Rehabilitation Engineering 
Society of North America in' Houston, Texas. 
Dr. Doris' Rouse met with Jack Wheeler, Technology Utilization Officer, Johnson 
Space Center, to discuss JSC transfer projects. 
Dr. Clark, Beall visited McGee Eye I nstitute in Oklahoma City, Oklahoma, with JPL 
and MSFC personnel to discuss the corneal topography project. 
Dr. James, Brown met with Ron Phillips at NASA Headquarters to discuss RTI's 
technology transfer program. 
Dr. Doris Rouse and RTI team consultants Bill Penland and Bernie Maggin partic-
ipated in the RTOP review at the NASA Scientific and Technical Information Facil-
ity, Baltimore/Washington International Airport, Maryland. 
Dr. James B'rown and Dr. Doris Rouse met with Ray Whitten in Washington, D.C., 
to discuss several team projects. ' 
Bill Penland! and Dr., Doris Rouse met with Dr. Emilie Black at NIH to discuss ultra-
sound analysis of burn, depth. 
Bill Penland, and Dr. Doris Rouse met with Bob Fischell at Applied Physics Labora-
tory in Laurel, Maryland, to discuss team assistance to APL in NASA Technology 
Utilization; projects. 
Dr. Doris Rouse, Bill Penland, and Dr. John Cantrell met with Dr. John Burke at 
the" Shriners' Burn, Institute, Massachusetts General Hospital, Boston, to discuss 
ultrasound analysis of burn depth. ' 
Dr. Doris, Rouse and, Dr. John Cantrell met with Sonometric Systems, Inc., in' New 
York to' discuss commercialization' of the ultrasound system for burn depth 
analysis. 
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October 19, 1982 Dr. James Brown met with Don Smith at the University of Michigan to discuss NASA 
technology transfer and robotics. 
October 20, 1982 Dr. James Brown met with Ray Whitten t9 discuss team projects. 
November 9-10, 1982 Dr. James Brown met with Reed Barnett at Kennedy Space Center to disGusS wild-
life tracking. . 
November 12-14, 1982 Dr. Doris Rouse and Don Friedman met with Tom Loarie, President of Heyer Schulte 
Corporation, to discuss tile microprocessor-based hydrocephalus shunt. These dis-
cussions were held during a workshop on hydrocephalus m~nageinent in Napa, 
California. 
November 15, 1982 
November 16, 1982 
November 17, 1982 
November 23, 1982 
December 6-7, 1982 
December 8-9, 1982 
December 14, 1982 
January 25, 1983 
January 31, 1983 
Dr. Doris Rouse met with SRI and the Veterans Administration Rehabilitation Engi-
neering Center in Palo Alto to discuss mobility aids for th~ blind. 
Dr. Doris Rouse met with Stan Miller at NASA Ames to discuss TU projects. 
Dr. H. Clark Beall met with Don Vargo and. Ray Whitten in Washington to discuss 
team projects. 
Dr. James Brown met with Ray Whitten to discuss team projects and plans. 
Dr. Doris Rouse participated in an Advisory Design Committee meeting for the 
Association for Retarded Citizens in Arlington, Texas. 
Dr. H. Clark Beall met with Don Vargo, Dr. Giannini I Sandy Felder, Don Friedman, 
and Case Western University researchers to discuss functional electrical stimulation. 
Dr. H. Clark Beall attended a presentation by Smith-Kettlewell researchers at 
Marshall Space Flight Center on the results of their evaluation of the ophthalmic 
screening device. 
Tony Sigmon met at Lewis Research Center with Harrison Allen and representatives 
for the Department ~f Energy and the Air Force to discuss a collaborative project 
on the magnetic heat pump. 
Tony Sigmon met at Kennedy Space Center with Reed Barnett and Ray Gilbert to 
discuss a Phase ° study on heat pipe applications. 
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TABLE B-1. SUMMARY OF BIOMEDICAL APPLICATIONS TEAM ACTIVITIES 
January 1, 1981 - December 31, 1981 
Activity 
New Projects 
Commercial Transfers 
I nstitutional Transfers 
Phase 0 Studies 
Inactivated Projects 
Current Active Projects 
Field Centers Visited 
Field Centers Participating in Team Projects 
Manufacturers Participating 
Medical Institutions Participating 
Health Agencies Participating 
lAC Information Searches 
Medical Literature Searches 
TABLE B-2. COMMERCIAL TRANSFERS 
Number 
6 
2 
2 
2 
5 
15 
7 
9 
38 
28 
21 
6 
12 
.Porta-Fib III Ocular Screening Device 
TABLE B-3. INSTITUTIONAL TRANSFERS 
Implant Materials Testing Incinerator Monitoring 
B-2 
TABLE B-4. 
Mopility Aids for the Blind 
TABLE B-5. 
Computerized Hydrocephalus Implantable Pump 
Hyperthermia Thermography 
I ncinerator Monitoring 
PHASE 0 STUDI ES 
Ultrasound Diagnosis of Burn D~pth 
NEW PROBLEMS 
Portable X-Ray Fluorescence Spectrometer 
Ultrasound Diagnosis of Burn Depth 
Wastewater Treatment by Vascular Aquatic Plants 
TABLE B-6. INACTIVATED PROJECTS 
Composite Material Applications 
Detection of a Dislodged Temperature Probe 
Fiber Optics System for Knee Surgery 
B-3 
Low Cost UV Optical Dosimeter 
Portable X-Ray Fluorescence Spectrometer 
TABLE B-7. ACTIVE PROJECTS AS OF FEBRUARY 28, 1983 
Computerized Hydrocephalus Implantable Pump 
Corneal Topography 
Digital Data Recorder 
High Performance Wheelchair 
Hydrocephalus Shunt--Ventilation 
Hyperthermia Thermography 
Microwave Thermography , 
Noninvasive Lung Diagnos~s, 
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Portable Cooling System for Quadriplegics 
Progr~mmable Implantable Medication System 
Prosthetic Urinary Sphinc-ter 
Texturing for Percutaneous Connectors 
Texturing Surfaces for Cardiovascular Prostheses 
Ultrasound Diagnosis of Burn Depth 
Wa'stewater Treatment by Vascular Aquatic Plants 
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APPENDIX C. NEW PROJECTS 
COMPUTERIZED HYDROCEPHALUS IMPLANTABLE P~MP (December 1982) 
BATeam Personnel: Dr. Doris Rouse 
Problem 
Hydrocephalus is an abnormal accumulation of cerebrospinal fluid (CSF) within the ventricles of the 
central nervous system. These ventricles are fluid-filled chambers that ~upport and protect the brain 
and spinal cord. Cerebrospinal fluid is normally produced at a rate of approximately 0.35 mL per 
minute or about 504 mL per day. Normal CSF volume is 50 mL in infants and 150 mL in adults. The 
CSF, therefore, is renewed completely every 8 hours. Pathways for circulation or absorption of CSF 
can be blocked by congenital defects, trauma, infections, or tumors. The resulting fluid accumulation 
results in dilated ventricles and increased intracranial pressure with clinical sequela of impaired cogni-
tive abilities, spasticity, or death. 
Surgical insertion of a tube to shunt the CSF from the ventricles to another body cavity is often the 
only treatment. Unfortunately, currently available shunts often drain too much or too little CSF 
causing ventricular collapse or increased intracranial pressure. 
Principals 
Mr. Don Friedman, Technology Utilization Officer i Goddard Space Flight Center. 
Solution 
A microprocessor-controlled shunt capable of measuring intracranial pressure and flow through the 
shunt would allow the neurosurgeon to adjust the shunt parameters to achieve optimal CSF diversion 
and normal ventricle size. This system would also allow the neurosurgeol1 to wean the patient gradu-
ally from dependence on the shunt for CSF diversion in some Cases. 
NASA Technology 
NASA technology in miniaturized, high-reliability fluid systems and microelectronics could be used in 
developi.ng a microprocessor-controlled shunt. . 
Cost to NASA 
An engineering feasibility study is planned for 1983 at an estimated cost of $100,000. 
C-2 
Commercialization Strategy 
The RTI team has discussed the project with two major manufacturers of CSF shunt systems. Both 
companies indicated an interest in a collaborative project with NASA. A request for proposals to 
develop the system design will be issued by Goddard Space Flight Center. 
Status 
The RTI team completed a Phase 0 Study this year. 
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HYPERTHERMIA THERMOGRAPHY (January 1982) 
BATeam Personnel: Dr. H. Clark Beall 
Problem 
The treatment of cancer by localized hyperthermia is a procedure receiving progressively more atten-
tion by oncologists. The generation of hyperthermia at localized sites within the human body can be 
accomplished by ultrasound irradiation, microwave irradiation, or radiofrequency irradiation. The sig-
nificant technical hindrance to the therapy is the requirement for knowledge of the precise temperature 
at the hyperthermia site within the body. Reports in the hyperthermia literature indicate that both 
the exact temperature and the duration of application must be monitored and controlled during hyper-
thermia session~. 
Solution 
NASA Headquarters assigned Langley Research Center the responsibility of devising a procedure for 
the remote measurement of the temperature within the human body. I nitial tests at Langley had shown 
that passive microwave sensing of temperature was not precise enough, or localized enough, to be 
useful during hyperthermia . 
. NASA Technology 
A meeting at the Langley Technology Utilization Office of NASA scientists and an RTI Biomedical 
Applications Team representative resulted in the derivation of several theoretical techniques for meas-
urement of temperature by remote means. The most feasible and mQst novel method involves the !-Ise 
of ultrasound for the detection of phase transitions within strategically located fat deposits within, or 
near, the hyperthermia site. . 
Principals 
Joe Heyman, Ph.D., NASA Langley Research Center, Hampton, Virginia 
H. Clark Beall, Ph. D., RTI Biomedical Applications Team, Research Triangle Park, North Carolina. 
Cost to NASA 
The feasibility of the temperature measurement scheme could be tested immediately in the laboratory at 
Langley with a model system at an anticipated cost of $20,000. 
Commercialization Strategy 
The eventual result of the effort for hyperthermia thermography is the development of an optimized 
ultrasound scan'ling system and a set of specially formulated fat compounds with sharply defined melt-
ing points. This custom apparatus should be of commercial value to manufacturers ~f ultrasound 
equipment and hyperthermia equipment. 
C-s 
Status 
The physical and physiolqgical bas.es of the new technique have been presented in the form of an 
advocacy package to NASA Heijdquarters. 
Action 
The RTI Biomedical Applications Team will assist the Langley ultrasound personnel in the selection of 
appropriate lipid compol,lnds for use in the proposed remote temperature measurement technique. 
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INCINERATOR MONITORING (January 1982) 
BATeam Personnel: Dr. H. Clark Beall 
Proplem 
The incineration of municipal r~fuse is a developing technology that not only disposes of wastes but 
also is a source of energy. Incineration is virtually the only disposal means for toxic, nonbiodegrad-
able compounds such as PCB or agent orange. Smokestack monitoring is necessary to ensure complete 
combustion and to prevent dispersal into the air pf noxious f~me~ and gases. A continuous, on-line 
monitoring program is desir:able so that defective combus~ion can be sensed immediately and corrected. 
Solution 
i· Mass spectroscopic analysis of flue gases appears to detect any of a Wide variety of common combusti()n 
products. The spectrometer can be tuned to detect fragments of organic molecules that differ in the 
presence of a single hydrogen atom or a single electronic charge. 
NASA Technology 
The General Instrumentation Branch at Langley Research Cent~r has an ongoing program of develop-
ment of, and applications for, quadrupole mass spectrometer systems. 
Principals 
George Wood, Jr., NASA Langley Research Center, Hampton, Virginia. 
Merril Jackson, U. S. Environmental Protection Agency (~PA), Research Triangle P~rk, North Carolina. 
Cost to NASA 
The spectrometer program at Langley is supported by mission funding. Modifications to the basic 
system for special applications require additional funding. 
Commercialization Strategy 
This spectrometer project would lead to the development. of a specialized controller, co!,,!sisting of hard-
ware and computer software, for application specifically to the monitoring of incinerators. Such tech-
nology would be commercially valuable for the extensive monitoring of incinerators nationwide. 
Status 
EPA is interested in the mass spectrometer as a device that is tunable and sensitive enough to monitor 
all emission products of interest and is also portable enough to be mounted in a van' for monitoring 
the environment of incinerators. In particular, EPA wishes to apply the mass spectrometer to the 
monitoring of a new hazardous waste incinerator that is b~ing constructed near Boston, Massachusetts. 
Action 
The RTI team has planned a meeting at the EPA facility in Research Triangle Park of p~rsonnel from 
EPA, NASA, and EPA contractors to discuss the proposed application and funding of the mass spec-
trometer program. 
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PORTABLE X";RAYFLUORESCENCE SPECTROMETER (January 1982) 
, , 
BATeamPersonnel : Dr. 'H. Clark Beall 
Problem 
The analysis of all elements present in a sample is a complex and expensive procedure. Moreover, 
geological and environmental sampling programs can Pfoceed more quickly if an immediate analysis for 
elements can be accomplished away from laboratory facilities . 
Solution 
Mass spectrometers, ion probe scanning electrpnmicroscopes, and X-ray fluorescence spectrometers 
are examples ofestablished:laboratory-based instruments that are capable of comprehensive elemental 
analysis. 'Historically, none of theseinstrum~"ts is considered to be portable enough to be carried 
into the field by one man .It :now'appear~, however, that the X-ray fluorescence spectrometer can 
be configured with modern solid-'state digital electronic 'circuitry and a display device to the extent 
that the complete system can ;be:contained in one portable device the size ofa small suitcase. 
NASA Technology 
A NASA contractor working 'with Langley Research Center has developed a portable X-ray fluorescence 
spectrorneter that is capable of analyzing X-ray-induced fluorescence in the range 5 keV to'100 keV. 
The instrument ,appears to have 'applications as an' analytical tool in the area of geological and environ-
mental sampling. 
Principals 
Warren 'Kelliher" 'NASA Langley Research Center, Hampton, Virginia. 
Cost to NASA 
The prototype instrument has already been developed for NASA mission applications. Thus, the device 
can be considered mature technology and can be used in other applications without further modification. 
,Commercialization 'Status 
Discussions continue between NASA and the NASA contractor concerning items of technology that were 
built into the X-,ray fluoresc~nce spectrometer. No commercialization efforts are appropriate until the 
patent status is resolved . 
Status 
Extensive applications testing of the device will not be required. The primary effort will be in the 
;development 'of appropriate sample preparation techniques for medical applications. 
Action 
:As soon as :the p~tent status 'Of the device is established I effprts can be directed to commercialization. 
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ULTRASOUND DIAGNOSIS OF BURN DEPTH (April 1982) 
BATeam Personnel: Blake S. Wilson 
Problem 
Approximately 2 million Americans. suffer serious burns each year, and 200 to 300 thousand of th~se 
people require hospital treatment, 1 Among those hospitalized, 70,000 receive intensive care and 10 to 
12 thousanq patients die from their injuries. The cost of intensive care exceeds $300 million per 
year. ~ The traditional treatment of burn victims is to allow natural debridement, sloughing of necrotic 
tissue, to occ!Jr and then to close the resulting open wounds with skin grafts. Unfortunately, the 
weeks required for spontaneQus sloughing often result in infection Clnd sepsis; illdeed, the major cause 
of death in burn victims is bacterial infection. 3 Modern treatment, therefore, is based on early recog-
nition and removal of necrotic tissue to reduce infection and hasten healing. This surgical or chemical 
debridement depends upon accurate burn depth information for optimal results. Current methods for 
burn depth determination are inaccurate, cumbersome, or both. . 
Solution . 
Ultrasound may be used to map precisely and conveniently the depths of the interface between viable 
and necrotic tissue in burn injuries. Preliminary studies in pigs demonstrate a good correlation 
between depths of burn measured by pulse-echo ultrasound and by histological techniques. 
NASA Technology 
Advanced Ultrasonic technology developed at Langley Research Center for the characterization of 
materials is directly applicable to this project. . 
. . 
Principals 
Dr. John H. Cantrell, Jr., Langley Research Center, Hampton, Virginia. 
Cost to NASA 
Estimated cost for development of the prototype is $180K. 
Commercialization Status 
The RTI team has contacted three medical ultrasou'1d system manufactl,Jrers. Responses are expected 
in the next quarter. 
Status 
An FY83 RTOP has been submitted by Langley Research Center for support of the project. Two major 
burn centers, Medical College of Virginia and the Baltimore Regional Burn ·Center, have indicated a 
strong interest in conducting the clinical evaluation of the system.· . 
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Action 
The RTI team and Dr. Cantrell will interview burn center personnel to identify the most appropriate 
clinical collaborators and funding sources. Discussions with manufacturers and NIH will continue. 
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WASTEWATER TREATMENT BY VASCULAR AQUATIC PLANTS (April 1982) 
BATeam Personnel: pr. H. Clark Beall 
Problem 
The purification of wastewater is a problem faced by municipal treatment plants throughout the United 
States. The effluent from such plants must meet standards set by EPA before it can be released from 
the treatment plant. Sanitation engineers are searching continually for new technologies that can be 
applied to water treatment to reduce costs, time, and en~rgy required to process wastewater. 
Solution 
Use of aquatic plants, one of several new procedures for wastewater trei;)tment, shows promise in terms 
of speed, operating cost, and effectiveness. I " 
NASA Technology 
Research at the National Space Technology. Laboratories has focused on the treatment of wastewater 
by vascular aquatic plants. The first effort dealt with a system based on the water hyacinth, Eich-
hornia crassipes. This system worked well in warm climates in wastewater treatment and biomass 
energy production. 
Princigals 
Bill Wolverton, Ph. D., National Space Technology Laboratories, Mississippi. 
Cost to NASA 
The current RTOP request fqr this work is $40K with an additional $80K being f"mdeq by EPA. 
Commercialization StrateflY 
The ~ity of S~n Diego is now using the water hyacinth system as one means to bring effluent water 
to potable standards. An engineering firm from Baton Rouge, Louisiana, Owens and White, Inc., has 
based its designs for two new municipal treatment plants on the NASA-publisheq data of microorganism/ 
vascular plant wastewater treatment. The designs are being reviewed by EPA and await local funding 
under the Innovative Tec~nology program of the State of Louisiana. 
Status 
Duril1g the last 2 years, NSTL "effort has centered upon evaluation of a hybrid system in which septic 
digestion is followed by a rock bed filter containing the common reed Phragmites communis. The reeq's 
rhizome system fluorishes in cold climates unlike the water hyacinth, which dies in cold weather. " 
C-11 
Action 
The technical acceptance of the hybrid reed system by the engineering firm of Owens and White, Inc., 
is expected to be followed by the funding of the technology and the construction of fu~ctioning urban 
systems. 
Reference 
Wolverton, B. C. New Hybrid Wastewater Treatment System Using Anaerobic Microorganisms and Reed 
(Phragmites communis). NASA Technical Memorandum, TM-X .. 72739, June 1981. 
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